var title_f19_13_19664="MRI of pheochromocytoma";
var content_f19_13_19664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of pheochromocytoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI of the abdomen shows a 4.5-cm right adrenal pheochromocytoma (arrows). Upper panel: T1-weighted image. Lower panel: T2-weighted image shows increased signal intensity typical of a pheochromocytoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William F Young, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19664=[""].join("\n");
var outline_f19_13_19664=null;
var title_f19_13_19665="Chest radiograph of supracardiac TAPVC";
var content_f19_13_19665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of supracardiac total anomalous pulmonary venous connection (TAPVC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posterior-anterior chest radiograph of a school-aged child with unrepaired supracardiac total anomalous pulmonary venous connection (TAPVC) demonstrating the findings that produce the classic snowman appearance. Note the marked dilation of the superior vena cava (SVC), innominate vein, and the silhouette produced by the vertical vein. Pulmonary vasculature is engorged, and the cardiac silhouette is mildly enlarged.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19665=[""].join("\n");
var outline_f19_13_19665=null;
var title_f19_13_19666="Prog activation of PR";
var content_f19_13_19666=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Progesterone (P) activation of the PR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 274px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Binding of P to the inactive receptor complex induces a conformation change, which leads to HSP dissociation, receptor dimerization, DNA binding, and recruitment of coactivators (SRC and CBP) to facilitate communication with the basal transcription apparatus.",
"    <div class=\"footnotes\">",
"     PRE: progesterone response element.",
"    </div>",
"    <div class=\"reference\">",
"     Leonhardt, SA, Edwards, DP. Exp Biol Med 2002; 227:969. Copyright &copy; 2005 Society for Experimental Biology and Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19666=[""].join("\n");
var outline_f19_13_19666=null;
var title_f19_13_19667="ER Barretts";
var content_f19_13_19667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic drawing showing the consecutive steps of the endoscopic resection-cap procedure of a focal lesion in a Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A and B) A transparent cap is attached to the distal tip of the endoscope and the target lesion is lifted by injection of a fluid, usually diluted epinephrine (1:100.000), into the submucosal layer, using a standard sclerotherapy needle.",
"    <br>",
"     (C and D) After removal of the needle, a crescent shaped snare is positioned into a distal ridge within the cap. The lesion is sucked into the cap thus creating a pseudo-polyp that is immediately captured by forcefully closing the pre-positioned EMR-snare.",
"     <br>",
"      (E) The lesion is removed using electrocoagulation.",
"      <div class=\"footnotes\">",
"       EMR: endoscopic mucosal resection.",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: www.Barrett.nl. Copyright &copy; Amsterdam Esophageal Research Foundation.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19667=[""].join("\n");
var outline_f19_13_19667=null;
var title_f19_13_19668="Potassium bicarbonate: Patient drug information";
var content_f19_13_19668=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Potassium bicarbonate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=see_link\">",
"     see \"Potassium bicarbonate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/26/42402?source=see_link\">",
"     see \"Potassium bicarbonate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13755838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      K-Effervescent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat low potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702763",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to potassium bicarbonate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703766",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If water pill is stopped, potassium will most often be stopped too. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695447",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       cup of water or juice and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12098 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19668=[""].join("\n");
var outline_f19_13_19668=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13755838\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012844\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012843\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012848\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012849\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012851\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012846\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012847\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012852\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012853\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=related_link\">",
"      Potassium bicarbonate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/26/42402?source=related_link\">",
"      Potassium bicarbonate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_13_19669="Lorazepam: Patient drug information";
var content_f19_13_19669=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lorazepam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     see \"Lorazepam: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     see \"Lorazepam: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ativan&reg;;",
"     </li>",
"     <li>",
"      Lorazepam Intensol&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lorazepam&reg;;",
"     </li>",
"     <li>",
"      Ativan&reg;;",
"     </li>",
"     <li>",
"      Dom-Lorazepam;",
"     </li>",
"     <li>",
"      Lorazepam Injection, USP;",
"     </li>",
"     <li>",
"      Novo-Lorazem;",
"     </li>",
"     <li>",
"      Nu-Loraz;",
"     </li>",
"     <li>",
"      PHL-Lorazepam;",
"     </li>",
"     <li>",
"      PMS-Lorazepam;",
"     </li>",
"     <li>",
"      PRO-Lorazepam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11263427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691707",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat alcohol withdrawal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat panic attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm you before care.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702412",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lorazepam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shot: If you have sleep apnea.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694293",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills. Mix with water, juice, or soft food before drinking or eating.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Mix with water. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699433",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (solution) in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10819 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19669=[""].join("\n");
var outline_f19_13_19669=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189926\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189927\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263427\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012352\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012351\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012356\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012357\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012359\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012354\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012355\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012360\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012361\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=related_link\">",
"      Lorazepam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=related_link\">",
"      Lorazepam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_13_19670="Quitting smoking";
var content_f19_13_19670=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Quitting smoking (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/13/19670/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19670/contributors\" id=\"au4395\">",
"       Joyce A Sackey, MD, FACP",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19670/contributors\" id=\"au1818\">",
"       Stephen I Rennard, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/13/19670/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19670/contributors\" id=\"se5969\">",
"       James K Stoller, MS, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19670/contributors\" id=\"se323\">",
"       Robert H Fletcher, MD, MSc",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/13/19670/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19670/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?19/13/19670?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Cigarette smoking is a major cause of disease in the United States. More than 400,000 deaths occur each year as a result of cigarette smoking [",
"     <a class=\"abstract\" href=\"UTD.htm?19/13/19670/abstract/1\">",
"      1",
"     </a>",
"     ]. In addition, exposure to second-hand smoke is estimated to cause 40,000 deaths each year from heart disease and contributes to other diseases as well. Smoking is a major cause of non-fatal diseases including osteoporosis, skin wrinkling, peptic ulcer disease, impotence, and pregnancy complications.",
"    </p>",
"    <p>",
"     Quitting and staying away from cigarettes is difficult, but not impossible. This topic review discusses the benefits of stopping smoking, treatments that can aid in the process of quitting, and the difficulties of relapse for those who try to quit.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      BENEFITS OF QUITTING SMOKING",
"     </span>",
"    </p>",
"    <p>",
"     Smoking cessation has major and immediate health benefits for men and women of all ages. The earlier you quit, the greater the benefits. People who quit smoking before age 50 reduce their risk of dying over the next 15 years by one-half, as compared to those who continue to smoke. Smoking cessation is also important to those who do not smoke since being exposed to second-hand cigarette smoke is responsible for a number of serious health conditions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Cardiovascular disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cigarette smoking doubles the risk of developing coronary heart disease, and smoking cessation can rapidly reduce this risk. One year after stopping smoking, the risk of dying from coronary heart disease is reduced by about one-half and continues to decline over time. In some studies, the risk of heart attack was reduced to the rate of nonsmokers within two years of quitting smoking.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Pulmonary disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Smoking increases the risk of long-term lung diseases such as chronic obstructive pulmonary disease. While much of the lung damage caused by smoking is not reversible, stopping smoking can reduce further damage to the lungs, and many smokers with a chronic cough and sputum (phlegm coughed up from the lungs) note an improvement in these symptoms during the first year after stopping smoking. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"      \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Asthma and sudden infant death syndrome (SIDS) are more common among children exposed to smoke. Cigarette smoking makes it more difficult to treat asthma.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cigarette smoking is responsible for almost 90 percent of cases of lung cancer. Smoking cessation reduces the risk of lung cancer within five years of stopping, although former smokers still have a higher risk of lung cancer than people who have never smoked. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"      \"Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Stopping smoking may also reduce the risk of other cancers, such as cancers of the head and neck, esophagus, pancreas, and bladder. Stopping smoking is beneficial even after one of these cancers is diagnosed, since it reduces the risk of getting a second cancer and may improve the chance of survival from the first cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Peptic ulcer disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cigarette smoking increases the risk of developing peptic ulcer disease. Smoking cessation decreases that risk and increases the rate of ulcer healing, if ulcers have developed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"      \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Osteoporosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Smoking increases bone loss and increases the risk of hip fracture in women. Stopping smoking begins to reverse this risk after about 10 years. Increased bone loss has also been noted in male smokers, although it is not clear how much a man's risk of fracture is increased by smoking. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      \"Patient information: Bone density testing (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Other diseases",
"     </span>",
"     &nbsp;&mdash;&nbsp;Smoking also causes or worsens many other conditions. As an example, pregnant women who smoke have an increased risk of birth defects and of having an underweight baby. Smoking causes premature skin wrinkling and increases the risk of sexual problems (eg, impotence). Stopping smoking probably reduces the risk of these conditions.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      RISKS OF QUITTING SMOKING",
"     </span>",
"    </p>",
"    <p>",
"     Generally, any risks of smoking cessation are far outweighed by the benefits. Nevertheless, it is reasonable to prepare for the discomforts of stopping smoking:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Symptoms of withdrawal are common while attempting to stop smoking. Symptoms generally peak in the first three days and decrease over the next three to four weeks.",
"       <br/>",
"       <br/>",
"       Withdrawal symptoms can include difficulty sleeping, irritability, frustration or anger, anxiety, difficulty concentrating, and restlessness. Episodic cravings for cigarettes, which can be intense, may persist for many months. Cravings may be brought on by situations associated with smoking, by stress, or by drinking alcohol. These cravings are a common time for ex-smokers to relapse. The cravings will go away if ignored.",
"      </li>",
"      <li>",
"       Some people who stop smoking experience depression; this can be severe enough that it requires counseling or antidepressant medication and it can cause the person to start smoking again.",
"       <br/>",
"       <br/>",
"       Depression may also be a side effect of some medications taken to help quit smoking. Symptoms of sleeplessness, irritability, sadness, difficulty concentrating, or other signs of depression should be discussed with a healthcare provider. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"        \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Weight gain can occur while stopping smoking because people tend to eat more after quitting. Typically, people gain two to five pounds in the first two weeks, followed by an additional four to seven pounds over the next four to five months. The average weight gain is 8 to 10 pounds.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     An exercise program and eating a reasonable diet can minimize weight gain. The benefits of quitting smoking are much greater than the risk of gaining weight. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      \"Patient information: Exercise (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      PREPARING TO QUIT",
"     </span>",
"    </p>",
"    <p>",
"     Smoking is recognized as a chronic addictive disease. Smokers, however, can differ markedly in the way in which they smoke. A few may not be addicted to smoking, although it is estimated that 85 percents of smokers in the United States are addicted. Even among those who are addicted, there may be marked differences in success in quitting, symptoms that occur when you try to quit, and factors that may lead to relapse. Discuss any prior attempts to quit with a healthcare provider to improve your chances of successfully quitting.",
"    </p>",
"    <p>",
"     After deciding to quit smoking, the first step is usually to set a quit date. This is the day when you will completely quit smoking. Ideally, this date should be in the next two weeks, although choosing a special date (eg, birthday, anniversary, or holiday) is another option.",
"    </p>",
"    <p>",
"     Some people switch to a brand of cigarettes that is lower in tar and nicotine before quitting, but this frequently causes the person to inhale more often or more deeply; low tar and low nicotine cigarettes have no known benefits and are not recommended. Reducing the number of cigarettes smoked prior to the quit date is recommended by some as a means of preparation.",
"    </p>",
"    <p>",
"     Other steps that may help in preparing to quit include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Tell family, friends, and coworkers about the plan to quit and ask for their support.",
"      </li>",
"      <li>",
"       Avoid smoking in the home and car and other places where you spend a lot of time.",
"      </li>",
"      <li>",
"       Review other quit attempts. What worked? What did not work? What contributed to relapse?",
"      </li>",
"      <li>",
"       Prepare to deal with nicotine withdrawal symptoms, including anxiety, frustration, depression, and intense cravings to smoke. Recalling previous quit attempts may help anticipate these symptoms. Withdrawal symptoms usually become manageable within a few weeks of stopping completely.",
"      </li>",
"      <li>",
"       Prepare to deal with things that trigger smoking. Examples include having smokers in the household or workplace, stressful situations, and drinking alcohol. A vacation from work may be an easier time to quit, particularly if you smoke during work breaks.",
"      </li>",
"      <li>",
"       Talk with a healthcare provider about ways to quit smoking. Changing behaviors and taking a medication are the two main methods of quitting smoking. You are more likely to quit if you use both methods together.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      BEHAVIORAL CHANGES TO HELP YOU QUIT",
"     </span>",
"    </p>",
"    <p>",
"     You can make changes in your behavior to help you quit smoking on your own or you can participate in individual or group sessions. Using behavioral changes with a medication increases your chances of success. (See",
"     <a class=\"local\" href=\"#H16\">",
"      'Medications for quitting'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Problem solving/skills training",
"     </span>",
"     &nbsp;&mdash;&nbsp;When preparing to quit, it is important to identify situations or activities that increase your risk of smoking or relapse. After identifying these situations, you may need to develop new coping skills. This may include one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Make lifestyle changes to reduce stress and improve quality of life, such as starting an exercise program or learning relaxation techniques. Vigorous exercise can enhance the ability to stop smoking and avoid relapse and also helps to minimize or avoid weight gain.",
"      </li>",
"      <li>",
"       Minimize time with smokers. People who live with smokers can consider negotiating with them to stop smoking at home or in the car.",
"      </li>",
"      <li>",
"       Recognize that cravings frequently lead to relapse. Cravings can be prevented to some degree by avoiding situations associated with smoking, by minimizing stress, and by avoiding alcohol. Cravings will subside. Keep oral substitutes (such as sugarless gum, carrots, sunflower seeds, etc.) handy for when cravings develop.",
"      </li>",
"      <li>",
"       Avoid thoughts like \"having one cigarette will not hurt\"; one cigarette typically leads to many more.",
"      </li>",
"      <li>",
"       Have as much information as possible about what to expect during a quit attempt and how to cope during this time. Self-help materials such as pamphlets, booklets, videos, or audio tapes; information from a healthcare provider; a counselor; a telephone hotline; the internet; and support groups can be helpful. Some medical centers have patient resources or learning centers with self-help materials. (See",
"       <a class=\"local\" href=\"#H28\">",
"        'Where to get more information'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Support",
"     </span>",
"     &nbsp;&mdash;&nbsp;Support can be very helpful in quitting smoking and staying off cigarettes. Support can come from family and friends, a healthcare provider, a counselor, a telephone hotline (in the US, 1-800-QUIT-NOW), or support groups. In addition to getting encouragement, it is important to have someone to discuss any problems that develop while trying to quit, such as depression, weight gain, lack of support from family and friends, or prolonged withdrawal symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Group counseling",
"     </span>",
"     &nbsp;&mdash;&nbsp;Group programs are offered by a number of organizations. They typically include lectures, group meeting, a tapering method leading to a \"quit day,\" development of coping skills, and suggestions for preventing relapse. The cost can vary from nothing to several hundred dollars.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Hypnosis and acupuncture",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hypnosis and acupuncture are popular stop-smoking methods. Although scientific support for these two methods is weak, some people who have failed with other techniques feel these treatments were helpful.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      MEDICATIONS FOR QUITTING",
"     </span>",
"    </p>",
"    <p>",
"     There are several medications that may help you stop smoking; in the United States, some of these are available without a prescription while others require a prescription. One of the most effective treatments is varenicline (Chantix&reg;), a prescription medication. Other options include nicotine replacement therapy and bupropion (Zyban&reg;, Wellbutrin&reg;). Any of these medications can have side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Nicotine replacement therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Without nicotine, most people develop withdrawal symptoms. These include depression, difficulty falling or staying asleep, irritability, frustration, anger, anxiety, difficulty concentrating, restlessness, and nicotine craving.",
"    </p>",
"    <p>",
"     Nicotine replacement therapy is designed to reduce the intensity of these symptoms, but will not prevent symptoms completely. Many smokers are able to quit without using nicotine replacement therapy, although nicotine is available to virtually anyone who desires it.",
"    </p>",
"    <p>",
"     Nicotine replacement therapy appears to be safe, even in people with known heart disease. However, using nicotine replacement along with smoking is",
"     <strong>",
"      not recommended",
"     </strong>",
"     .",
"    </p>",
"    <p>",
"     Nicotine is available in several forms: as a gum or lozenge, patch, nasal spray, or inhaler. None of these forms is significantly superior to another, and all appear similarly effective [",
"     <a class=\"abstract\" href=\"UTD.htm?19/13/19670/abstract/2\">",
"      2",
"     </a>",
"     ]. However, individual smokers may find one form particularly effective. Combinations of these therapies (usually a patch plus gum, lozenges, nasal spray, or inhaler) are probably more effective than use of one form alone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Gum",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nicotine gum contains nicotine that is slowly released with chewing. Gum is available in 2 mg and 4 mg pieces.",
"    </p>",
"    <p>",
"     People who smoke 25 cigarettes per day or less can use 2 mg of nicotine gum when needed. Smokers who smoke more than 25 cigarettes per day can use the 4 mg dose; this produces blood levels of nicotine 40 percent lower than smoking. Withdrawal symptoms are not prevented by gum use, but the intensity of the symptoms may be reduced. However, smokers can become chronic gum users.",
"    </p>",
"    <p>",
"     When used with an intensive behavioral program, nicotine gum can double your chances of quitting. Without a behavioral program, quit rates with gum are usually lower. Gum use is generally recommended for three to six months.",
"    </p>",
"    <p>",
"     There are disadvantages of using nicotine gum. Some people have a low oral pH (acidity) that reduces the absorption of nicotine. To be effective, the nicotine must be absorbed through the cheek or gums rather than swallowed. Swallowed nicotine can cause stomach upset and is not very effective for treating nicotine withdrawal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Lozenges",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nicotine lozenges slowly release nicotine into the saliva in the mouth. The nicotine works similarly to the gum, as it must be absorbed in the mouth and not swallowed. Because the lozenges do not require chewing, they may be easier for some people to use.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Skin patches",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nicotine patches deliver nicotine to the blood through a skin patch. Several doses are available. The highest dose patch (21 to 22",
"     <span class=\"nowrap\">",
"      mg/patch)",
"     </span>",
"     delivers nicotine at a rate about half as high as that of a thirty cigarette per day smoker. Withdrawal symptoms are reduced in intensity, but not eliminated.",
"    </p>",
"    <p>",
"     The combination of an intensive behavioral program and nicotine patches can double your chances of quitting.",
"    </p>",
"    <p>",
"     Treatment with nicotine patches is generally recommended at \"full dose\" for four to six weeks. Some brands of patches include a tapering period of several additional weeks. Longer use of nicotine patches does not generally improve the chance of quitting.",
"    </p>",
"    <p>",
"     Use of nicotine at night may interfere with sleep, causing vivid dreams. On the other hand, use of nicotine patches at night increases morning blood nicotine levels, which may help prevent difficult early morning withdrawal symptoms. There is a low risk of addiction with nicotine patches.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Nasal spray",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nicotine nasal spray delivers a liquid solution of nicotine to the nose. Compared to the patch and gum, the nasal spray produces a relatively rapid rise in nicotine levels in the blood, similar to what happens when you smoke. However, nasal irritation is common, occurring in 94 percent of people during the first two days of use and continuing in many after three weeks of treatment. Nasal sprays are safe. However, sprays can prolong nicotine addiction more than other forms of nicotine replacement.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Inhaler",
"     </span>",
"     &nbsp;&mdash;&nbsp;The nicotine inhaler is made up of a mouthpiece and a plastic cartridge that contains nicotine. Nicotine is released when you inhale through the device. Because most of the nicotine is deposited in the mouth, nicotine is absorbed slowly, which may make it less effective for treating cravings.",
"    </p>",
"    <p>",
"     Irritation of the mouth or throat is common, particularly in the beginning. People with asthma or chronic cough may not be able to use the inhaler due to throat irritation.",
"    </p>",
"    <p>",
"     Nicotine inhalers are available by prescription in the United States, but are one of the most expensive types of nicotine replacement.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Combinations of nicotine replacement",
"     </span>",
"     &nbsp;&mdash;&nbsp;Using a combination of two nicotine replacement products may be more effective than using one form alone. However, use of these combinations should be supervised by a knowledgeable healthcare provider.",
"    </p>",
"    <p>",
"     Examples of combination treatment include a nicotine patch, which may be worn to provide a constant low level of nicotine, and nicotine gum, which may be used as needed for cigarette cravings.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Varenicline",
"     </span>",
"     &nbsp;&mdash;&nbsp;Varenicline (Chantix&reg;) is a prescription medication that works in the brain to reduce nicotine withdrawal symptoms and cigarette cravings. In several studies, it was more effective than both bupropion and placebo (a look-alike substitute that contains no medication) [",
"     <a class=\"abstract\" href=\"UTD.htm?19/13/19670/abstract/3-5\">",
"      3-5",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     It should be taken after eating with a full glass of water as follows:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       One 0.5 mg tablet daily for three days",
"      </li>",
"      <li>",
"       One 0.5 mg tablet twice daily for the next four days",
"      </li>",
"      <li>",
"       One 1.0 mg tablet twice daily starting at day seven",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     You should try to quit smoking one week after starting varenicline. You should continue it for 12 weeks before determining if it is working; if you successfully quit at 12 weeks, you may continue taking it for an additional 12 weeks. If you have not quit after taking varenicline for 12 weeks, talk to your healthcare provider about the next step. Options include working harder to make behavioral changes and continuing varenicline or switching to another treatment.",
"    </p>",
"    <p>",
"     Common side effects of varenicline include nausea and abnormal dreams.",
"    </p>",
"    <p>",
"     In 2007, the US Food and Drug Administration (FDA) informed healthcare providers of a small number of people who developed suicidal thoughts and aggressive and erratic behavior during treatment with varenicline [",
"     <a class=\"abstract\" href=\"UTD.htm?19/13/19670/abstract/6\">",
"      6",
"     </a>",
"     ]. Although some of these thoughts and behaviors may have been due to quitting smoking rather than varenicline, the report states that not all such patients had discontinued smoking. If you develop agitation, depression, unusual behavior changes, or thoughts of suicide, you should stop varenicline and call your healthcare provider. Similarly, if you have a past history of mood or behavior problems, discuss this with your healthcare provider before taking varenicline.",
"    </p>",
"    <p>",
"     In 2011, the FDA issued an advisory that, in people who already have heart or blood vessel disease, varenicline may increase the risk of acute heart problems [",
"     <a class=\"abstract\" href=\"UTD.htm?19/13/19670/abstract/7\">",
"      7",
"     </a>",
"     ]. If you have a history of heart or blood vessel disease, discuss your condition with your healthcare provider before taking varenicline. If you already take varenicline, ask your healthcare provider whether you should consider switching to another medication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Bupropion",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bupropion (Zyban&reg;, Wellbutrin&reg;) is an antidepressant that can be used to help you stop smoking. It is usually taken once daily for three days, then increased to twice daily starting two weeks before the quit date; it is typically continued for 7 to 12 weeks. Bupropion may be more effective than nicotine replacement therapy, and combining the two may be even more effective.",
"    </p>",
"    <p>",
"     Bupropion is generally well tolerated, but it may cause dry mouth and difficulty sleeping. The drug is not recommended for those who have a seizure disorder, head trauma, anorexia nervosa, or bulimia, or who drink alcohol excessively.",
"    </p>",
"    <p>",
"     Similar to varenicline, if you develop agitation, depression, unusual behavior changes, or thoughts of suicide, you should stop bupropion and call your healthcare provider. If you have a past history of mood or behavior problems, discuss this with your healthcare provider before taking bupropion.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      RELAPSE",
"     </span>",
"    </p>",
"    <p>",
"     Most smokers make many attempts to quit before they are able to quit completely. Smoking is a \"relapsing\" condition, and relapse should not be thought of as failures. Each quit should be regarded a victory, and the longer it lasts, the better.",
"    </p>",
"    <p>",
"     However, if relapse occurs, it is important to understand why so that your next attempt will be more successful. Keep this in mind when attempting to quit for the first time. If you have success for a while, you can learn what helped and what did not and try again. Try to figure out the reasons that led to start smoking again, and determine if you used the methods (medication, counseling) correctly. Then explore solutions to use next time. Consider trying different methods or combinations of methods.",
"    </p>",
"    <p>",
"     Most relapses occur in the first week after quitting, when withdrawal symptoms are strongest. Try to mobilize support resources (eg, family, friends) during this critical time. Consider rewards for not smoking; use the money saved on cigarettes for a special treat such as a massage, a movie, a new outfit, or a special dinner.",
"    </p>",
"    <p>",
"     Later relapses often occur during stressful situations or with social situations that are associated with smoking, often combined with drinking alcohol. Being aware of these high-risk situations may help.",
"    </p>",
"    <p>",
"     If other problems, such as depression or alcohol or drug dependency, make it more difficult to quit, consider getting professional help from a healthcare provider or counselor. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H27\">",
"     <span class=\"h1\">",
"      WHERE DO I START?",
"     </span>",
"    </p>",
"    <p>",
"     The following steps are recommended to start the process of quitting smoking:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Talk to your healthcare provider about the method you plan to use to quit. Behavior changes should usually be combined with a medication (eg, varenicline, nicotine replacement therapy, or bupropion).",
"      </li>",
"      <li>",
"       Pick a date to quit smoking. Tell friends and family about your plan.",
"      </li>",
"      <li>",
"       Seek support through free telephone quitlines (eg, in the US, 1-800-QUIT-NOW)",
"      </li>",
"      <li>",
"       Begin making changes in your behavior &mdash; avoid situations that lead you to smoke.",
"      </li>",
"      <li>",
"       Start varenicline or bupropion one week before your quit date or start nicotine replacement on the day you quit.",
"      </li>",
"      <li>",
"       Deal with withdrawal symptoms as they develop. Consider using nicotine replacement therapy (such as nicotine patch, gum, or lozenge) to help manage withdrawal symptoms. Do not \"smoke just one\" to get through a rough day. Consult support groups for more tips on coping with withdrawal.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287370222\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292592983\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=see_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/13/11475?source=see_link\">",
"      Patient information: Lung cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/44/3779?source=see_link\">",
"      Patient information: Non-small cell lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/38/24162?source=see_link\">",
"      Patient information: Small cell lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/7/8307?source=see_link\">",
"      Patient information: Ankylosing spondylitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21156?source=see_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/37/44625?source=see_link\">",
"      Patient information: Schizophrenia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/6/37987?source=see_link\">",
"      Patient information: Heart attack recovery (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=see_link\">",
"      Patient information: Common wrist injuries (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/5/3155?source=see_link\">",
"      Patient information: Finger fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39330?source=see_link\">",
"      Patient information: Clavicle fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/33/14867?source=see_link\">",
"      Patient information: Hip fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/53/41810?source=see_link\">",
"      Patient information: Rib fractures in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/33/12819?source=see_link\">",
"      Patient information: Shinbone fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/63/27635?source=see_link\">",
"      Patient information: Vertebral compression fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/25/40338?source=see_link\">",
"      Patient information: Ankle fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/6/5219?source=see_link\">",
"      Patient information: Boxer&rsquo;s fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/22/355?source=see_link\">",
"      Patient information: Toe fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/21/5459?source=see_link\">",
"      Patient information: Pelvic fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/0/15363?source=see_link\">",
"      Patient information: Neck fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/54/7012?source=see_link\">",
"      Patient information: Coronary heart disease in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/37/595?source=see_link\">",
"      Patient information: Secondhand smoke: Risks to children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292593000\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5189?source=see_link\">",
"      Smoking and cardiovascular risk in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"      Smoking and pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungusa.org/\">",
"      www.lungusa.org/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       QuitNet",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.quitnet.com/\">",
"      www.quitnet.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Quitworks",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.trytostop.org/\">",
"      www.trytostop.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Agency for Health Care Research and Quality",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ahrq.gov/consumer/tobacco/\">",
"      www.ahrq.gov/consumer/tobacco/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?19/13/19670/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?19/13/19670?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19670/abstract/1\">",
"      Bergen AW, Caporaso N. Cigarette smoking. J Natl Cancer Inst 1999; 91:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19670/abstract/2\">",
"      Lancaster T, Stead L, Silagy C, Sowden A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ 2000; 321:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19670/abstract/3\">",
"      Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19670/abstract/4\">",
"      Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19670/abstract/5\">",
"      Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007; :CD006103.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/cder/drug/early_comm/varenicline.htm (Accessed on November 26, 2007).",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm259161.htm (Accessed on June 16, 2011).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f19_13_19670=[""].join("\n");
var outline_f19_13_19670=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           BENEFITS OF QUITTING SMOKING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           RISKS OF QUITTING SMOKING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           PREPARING TO QUIT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           BEHAVIORAL CHANGES TO HELP YOU QUIT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           MEDICATIONS FOR QUITTING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           RELAPSE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H27\">",
"           WHERE DO I START?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f19_13_19671="Anencephaly 2";
var content_f19_13_19671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71153%7EOBGYN%2F50131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71153%7EOBGYN%2F50131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Anencephaly at 12",
"    <sup>",
"     1/7th",
"    </sup>",
"    weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Sagittal view of the fetus. Note the unusual shape of the fetal head and the lack of surrounding cranium. B) Transverse section showing the abnormal shape of the head, with some dysmorphic brain tissue 'hanging' from the side of the head. The orbits are prominent. The amniotic fluid is echogenic as compared with the extraembryonic space; this is due to tissue debris from the disintegrating brain. C) Three-dimensional ultrasound reconstruction of the fetus demonstrating the abnormal head shape (arrows point to the fetal head).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Anencephaly at 32 postmenstrual weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 187px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A coronal view of the face. the eyes are prominent and above them no cranial vault or brain tissue is seen (A). A longitudinal view of the neck region and upper thoracic vertebrae showing the disrupted bony structures as well as some disorganized neutral tissue (B). In a transverse view the typical U-shaped vertebrae with tissue protruding is evident. This is consistent with an open upper spina bifida which is commonly seen with anencephaly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19671=[""].join("\n");
var outline_f19_13_19671=null;
var title_f19_13_19672="Pathophysiology of renal tubular acidosis and the effect on potassium balance";
var content_f19_13_19672=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/13/19672/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19672/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/13/19672/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19672/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/13/19672/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19672/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/13/19672/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major forms of renal tubular acidosis (RTA). Each has a different mechanism by which the acidosis occurs, resulting in different clinical manifestations (",
"    <a class=\"graphic graphic_table graphicRef58428 \" href=\"UTD.htm?22/42/23211\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10759?source=see_link\">",
"     \"Overview of renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal or type 1 RTA is associated with a defect in distal hydrogen ion excretion (",
"      <a class=\"graphic graphic_table graphicRef56437 \" href=\"UTD.htm?17/48/18188\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Proximal or type 2 RTA is characterized by a reduction in proximal bicarbonate reabsorptive capacity (",
"      <a class=\"graphic graphic_table graphicRef68165 \" href=\"UTD.htm?22/4/22604\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hypoaldosteronism or type 4 RTA is associated with hyperkalemia and mild metabolic acidosis (",
"      <a class=\"graphic graphic_table graphicRef82440 \" href=\"UTD.htm?41/0/41995\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the pathophysiology of the different forms of RTA and the impact these changes have on potassium balance. The major causes, diagnosis, and treatment of RTA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=see_link\">",
"     \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF URINARY POTASSIUM EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium balance is frequently abnormal in the different forms of RTA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. How this occurs will be described below but it is useful to begin by briefly reviewing normal renal potassium handling [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Almost all of the filtered potassium is reabsorbed passively in the proximal tubule and loop of Henle. As a result, most of urinary potassium is derived from potassium secretion in the distal nephron, particularly by the principal cells in the cortical collecting tubule. This process is primarily influenced by two factors: aldosterone; and the distal delivery of sodium and water, both of which promote sodium reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=see_link\">",
"     \"Chapter 12B: Renal potassium excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aldosterone acts in part by increasing the number of open sodium channels in the luminal membrane, thereby stimulating sodium reabsorption.",
"     </li>",
"     <li>",
"      The reabsorption of cationic sodium makes the lumen relatively electronegative, creating a favorable electrical gradient for passive potassium secretion from the tubular cell into the lumen through specific potassium channels in the luminal membrane.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DISTAL (TYPE 1) RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal or type 1 RTA is characterized by impaired distal hydrogen ion secretion. This defect leads to an inability to excrete the daily acid load (50 to 100 meq with a typical western diet), resulting in progressive hydrogen ion retention and a serum bicarbonate concentration that occasionally falls below 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the absence of alkali therapy.",
"   </p>",
"   <p>",
"    Distal RTA is also associated with variable changes in potassium balance and the serum potassium concentration, depending upon both therapy and the underlying defect [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Hypokalemia is common and may be so severe (serum potassium below 2",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    that patients present with muscle paralysis or even respiratory arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distal hydrogen secretion via luminal H-ATPase pumps primarily occurs in the type A or alpha intercalated cells in the collecting tubules (",
"    <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"     figure 1",
"    </a>",
"    ), which are also the site of potassium-secreting principal cells. Proper development of intercalated and principal cells is required for normal functioning of the collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different defects in distal acid secretion have been identified in distal RTA, and can produce different changes in potassium balance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=see_link&amp;anchor=H5#H5\">",
"     \"Chapter 11A: Renal hydrogen excretion\", section on 'Distal acidification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Decreased net activity of the proton pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diminished H-ATPase activity is thought to be the most common cause of distal RTA, resulting in an inability to establish a normally acid urine and therefore a urine pH that is persistently 5.5 or higher. Occasional patients (2 of 17 in one study) can acidify their urine below this level, but have an acidification defect that can be demonstrated with other diagnostic techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is likely that a number of different defects can directly or indirectly cause this problem (",
"    <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several patients with Sj&ouml;gren's syndrome have been reported in whom immunocytochemical analysis of tissue obtained by renal biopsy showed complete absence of H-ATPase pumps in the intercalated cells [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. How immunologic injury leads to this change is not known. High titers of an autoantibody directed against carbonic anhydrase II have also been described in some patients with Sj&ouml;gren's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/14\">",
"       14",
"      </a>",
"      ]. Inhibition of this enzyme by the autoantibodies reduces the number of hydrogen ions generated within the cell for secretion into the lumen.",
"     </li>",
"     <li>",
"      Mutations in the gene for the chloride-bicarbonate exchanger (AE1 or band 3) have been described in autosomal dominant (most common) and autosomal recessive distal RTA [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/15-24\">",
"       15-24",
"      </a>",
"      ]. This exchanger is responsible for returning to the systemic circulation the bicarbonate that is generated within the cell during hydrogen ion secretion (",
"      <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"       figure 1",
"      </a>",
"      ). Mutations in the exchanger can impair hydrogen secretion by at least two mechanisms: malfunction of the exchanger prevents bicarbonate exit from the cell, and the ensuing rise in cell pH impedes hydrogen ion secretion; or aberrant trafficking of the exchanger to the luminal membrane can result in bicarbonate secretion into the lumen where it neutralizes secreted hydrogen [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. Mutations in AE1 in red cells can lead to hereditary spherocytosis and southeast Asian ovalocytosis, both of which have been associated with RTA [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link&amp;anchor=H7#H7\">",
"       \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\", section on 'Band 3 defects'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15623?source=see_link&amp;anchor=H9#H9\">",
"       \"Hereditary elliptocytosis: Clinical features and diagnosis\", section on 'Southeast Asian ovalocytosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mutations in the genes encoding the B1 and alpha4 subunits of the H-ATPase pump can lead to impaired pump function [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/20\">",
"       20",
"      </a>",
"      ]. Defects in either subunit may also be associated with sensorineural deafness, suggesting that the pump is also required for normal function of the inner ear [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Untreated patients with a proton pump defect tend to waste potassium and become hypokalemic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/2\">",
"     2",
"    </a>",
"    ]. The potassium wasting is in part related to the reduction in distal hydrogen secretion via one or both of the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In order to maintain electroneutrality as sodium is reabsorbed in the distal nephron, potassium secretion must be enhanced to compensate for the diminished secretion of hydrogen. The potassium wasting is largely reversed by alkali therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      or sodium citrate), which increases bicarbonate delivery to the distal nephron. The rise in distal luminal pH allows more hydrogen to be secreted without reaching a limiting pH gradient, thereby decreasing the need for enhanced potassium secretion. Thus, hypokalemia tends to resolve with treatment of the acidemia unless the defect in H-ATPase activity is so severe that hydrogen secretion cannot be enhanced. Another mechanism that may reduce potassium secretion with alkali therapy is reduced aldosterone secretion induced by the associated volume expansion.",
"     </li>",
"     <li>",
"      The acid-secreting intercalated cells in the cortical and outer medullary collecting tubules have, in addition to a H-ATPase pump, a H-K-ATPase pump that secretes hydrogen and reabsorbs potassium [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/33\">",
"       33",
"      </a>",
"      ]. The function of this pump is probably more closely related to potassium balance, since its activity increases in response to potassium depletion. Decreased activity of this pump would reduce potassium reabsorption and therefore promote potassium excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Increased luminal membrane permeability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to form and maintain a highly acid urine requires the luminal membrane to be relatively impermeable to hydrogen ions or carbonic acid (H2CO3). A urine pH of 5.0, for example, represents a hydrogen concentration that is 250 times greater than the concentration at a normal extracellular pH of 7.40.",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is the primary cause of distal RTA due to enhanced membrane permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    .) Both the fall in hydrogen secretion and increased membrane permeability to potassium contribute to potassium wasting and the frequent development of hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/35\">",
"     35",
"    </a>",
"    ]. As with a proton pump defect, alkali therapy should decrease urinary potassium losses in this setting, since more hydrogen can be secreted without reaching the limiting pH gradient. Alkali therapy would not be expected to reduce potassium wasting related to increased membrane permeability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diminished sodium reabsorption in the adjacent principal cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium reabsorption in the principal cells in the cortical collecting tubule indirectly influences net hydrogen secretion by the intercalated cells in this segment. The transport of sodium from the lumen into the cell (and then the extracellular fluid) at a rate that exceeds the reabsorption of the accompanying anion (mostly chloride) makes the lumen electronegative. This negative charge promotes the secretion of both potassium and hydrogen.",
"   </p>",
"   <p>",
"    On the other hand, any process that impairs sodium reabsorption in the principal cells will tend to induce both metabolic acidosis and",
"    <strong>",
"     hyperkalemia",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This type of defect has been called a distal &ldquo;voltage-dependent&rdquo; RTA.",
"   </p>",
"   <p>",
"    This defect in humans has been described with urinary tract obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/36\">",
"     36",
"    </a>",
"    ] (in which tubular injury may diminish sodium reabsorption by reducing the activity of the cellular Na-K-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/37\">",
"     37",
"    </a>",
"    ]), sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/38\">",
"     38",
"    </a>",
"    ], lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/39\">",
"     39",
"    </a>",
"    ], and with any cause of marked volume depletion in which distal sodium delivery is substantially reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/40\">",
"     40",
"    </a>",
"    ]. These patients appear to have normal amounts of H-ATPase in the intercalated cells.",
"   </p>",
"   <p>",
"    Hyperkalemic distal voltage-dependent RTA has many features in common with type 4 RTA in which hypoaldosteronism (due to either decreased secretion or tissue resistance) leads to a rise in the serum potassium concentration. The main difference is that patients with hypoaldosteronism can usually lower the urine pH to 5.3 or less and have only a mild metabolic acidosis with a serum bicarbonate concentration generally above 17",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, correction of the hyperkalemia usually normalizes the serum bicarbonate concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link&amp;anchor=H15#H15\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Treatment'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In contrast, patients with distal voltage-dependent RTA generally have normal aldosterone levels, a more severe distal acidification defect, leading to a urine pH that is 5.5 or higher, and more severe metabolic acidosis with a serum bicarbonate concentration that is often below 15",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    However, the distinction between hyperkalemic distal RTA and type 4 RTA is not always clear. Some patients appear to have a defect in the proton pump that is responsible for the metabolic acidosis, while concurrent hypoaldosteronism or aldosterone resistance due to tubular damage is responsible for the hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Incomplete distal RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with incomplete distal RTA have a urine pH that is persistently 5.5 or higher plus hypocitraturia, as in the complete forms of RTA. However, these patients are able to maintain net acid excretion and the serum bicarbonate concentration in the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/3,43\">",
"     3,43",
"    </a>",
"    ]. Normal rates of acid excretion are achieved by an increase in ammonium excretion, which offsets the reduction in titratable acid excretion that is induced by the high urine pH.",
"   </p>",
"   <p>",
"    The pathogenesis of incomplete distal RTA is not well understood but the low rate of citrate excretion and the relatively high rate of ammonium excretion are consistent with a reduction in the intracellular pH within the cells of the",
"    <strong>",
"     proximal tubule",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/44\">",
"     44",
"    </a>",
"    ]. The proximal tubule is the site at which ammonia is generated and most of the filtered citrate is reabsorbed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/45\">",
"     45",
"    </a>",
"    ]. A primary proximal intracellular acidosis could initiate the following sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ammonium and hydrogen secretion into the lumen are enhanced. This is similar to the normal adaptation to metabolic acidosis, a response that is mediated at least in part by a fall in intracellular pH.",
"     </li>",
"     <li>",
"      The increased availability of hydrogen ions in the tubular lumen will convert the filtered trivalent citrate anion into the divalent form, which is more easily reabsorbed via a sodium-citrate cotransporter in the luminal membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/45\">",
"       45",
"      </a>",
"      ]. In addition, the intracellular acidosis would increase the metabolism of cell citrate; the ensuing reduction in cell citrate levels favors citrate entry from the tubular lumen into the cell [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Much of the secreted ammonium is reabsorbed in the loop of Henle and the ammonia is then recycled within the medulla and secreted into the medullary collecting tubule where it drives the following reaction to the right, lowering the free hydrogen ion concentration which will raise the urine pH:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;NH3 &nbsp; + &nbsp; H+ &nbsp; &nbsp;&harr; &nbsp; &nbsp;NH4+",
"   </p>",
"   <p>",
"    Two possible pathogenic mechanisms have been proposed to explain the reduction in proximal tubule intracellular pH in incomplete distal RTA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first event is a subtle distal acidification defect, leading to a fall in serum bicarbonate into the low-normal range and even intermittent episodes of overt metabolic acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. This causes an intracellular acidosis in the proximal tubule cells that leads to both increased ammonia synthesis and excretion and reduced urinary citrate excretion. Early in the course, the increase in ammonium excretion can almost entirely compensate for the distal acidification defect, resulting in maintenance of a near normal or normal serum bicarbonate concentration.",
"     </li>",
"     <li>",
"      The primary defect may be an intracellular acidosis in the proximal tubule [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/44\">",
"       44",
"      </a>",
"      ]. This will initiate the same sequence described in the first mechanism, beginning with increased ammonia synthesis and reduced urinary citrate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over a period of time, some patients with incomplete distal RTA progress to the complete form. Both the toxic effect of high interstitial ammonia concentrations and calcium phosphate precipitation (due both to the high urine pH and low urine citrate) may contribute to the increasing tubular injury in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42786907\">",
"    <span class=\"h1\">",
"     PROXIMAL (TYPE 2) RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal or type 2 RTA is characterized by a decrease in proximal bicarbonate reabsorptive capacity, resulting in a fall in the serum bicarbonate concentration. Several factors play an important role in normal bicarbonate reabsorption (",
"    <a class=\"graphic graphic_figure graphicRef60730 \" href=\"UTD.htm?8/8/8335\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=see_link&amp;anchor=H4#H4\">",
"     \"Chapter 11A: Renal hydrogen excretion\", section on 'Proximal acidification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sodium-hydrogen exchanger in the luminal membrane which pumps intracellular hydrogen ions into the lumen",
"     </li>",
"     <li>",
"      The Na-K-ATPase pump in the basolateral membrane that provides the energy for sodium-hydrogen exchange by maintaining a low cell sodium concentration and therefore a favorable gradient for passive sodium entry into the cell",
"     </li>",
"     <li>",
"      The enzyme carbonic anhydrase, which is located both in the cells, where it results in the generation of hydrogen and bicarbonate, and in the lumen, where it facilitates bicarbonate reabsorption by catalyzing the dehydration of the H2CO3 that is formed by the combination of filtered bicarbonate with secreted hydrogen ions",
"     </li>",
"     <li>",
"      The sodium-bicarbonate cotransporter, which is the principal mediator of bicarbonate transport across the basolateral membrane from the cell into the peritubular capillary",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is likely that one or more of these factors must be impaired to account for the bicarbonate reabsorptive defect in proximal RTA. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inherited defects in the gene for the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      cotransporter (SLC4A4) result in autosomal recessive proximal RTA (with concurrent ocular abnormalities) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/48,49\">",
"       48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mutations in the gene for one of the plasma membrane sodium-hydrogen exchangers may be responsible for autosomal dominant disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with mutations in carbonic anhydrase II, called carbonic anhydrase II deficiency syndrome, have a clinical picture of proximal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      distal RTA plus osteopetrosis, cerebral calcification, and, in many patients, mental retardation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/50-52\">",
"       50-52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Drugs that inhibit carbonic anhydrase, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      , and others, also generate a proximal RTA with variable distal acidification abnormalities. They can affect both carbonic anhydrase IV (the membrane bound isoform which acts within the tubule lumen) and carbonic anhydrase II which acts within the epithelial cells to generate protons and HCO3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the mechanism, the degree of acidosis is self-limited in proximal RTA. The serum bicarbonate concentration usually stabilizes at 14 to 20",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    depending upon both the severity of the proximal defect and the ability of the distal nephron to reabsorb excess bicarbonate coming out of the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/53\">",
"     53",
"    </a>",
"    ]. The magnitude of the distal nephron effect was illustrated in a child who had no demonstrable proximal tubular function in whom the serum bicarbonate concentration did not fall below 11 to 12",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42786914\">",
"    <span class=\"h2\">",
"     Effect on potassium excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal RTA is associated with variable changes in potassium excretion and the serum potassium concentration, depending upon whether or not the patient is being treated with alkali therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of alkali therapy, the serum bicarbonate concentration will fall until there has been a sufficient reduction in the filtered bicarbonate load so that all of the filtered bicarbonate can be reabsorbed, as occurs in normal subjects. In this setting, the serum bicarbonate concentration remains stable (usually between 12 and 20",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      the urine pH may be normally acid, and the serum potassium concentration is relatively normal. There may be some tendency to potassium wasting [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/2\">",
"       2",
"      </a>",
"      ], since metabolic acidosis diminishes proximal sodium reabsorption [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/55\">",
"       55",
"      </a>",
"      ]. Both the associated increase in distal sodium delivery and sodium-wasting-induced secondary hyperaldosteronism promote potassium secretion in the distal nephron and enhance potassium excretion.",
"     </li>",
"     <li>",
"      The findings are dramatically different when alkali therapy is begun in an effort to correct the acidemia. Raising the serum bicarbonate concentration increases the filtered load above proximal reabsorptive capacity. The ensuing marked elevation in distal sodium and water delivery will usually substantially enhance distal potassium secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/2,56\">",
"       2,56",
"      </a>",
"      ]. Thus, most patients who are treated with alkali therapy require a combination of potassium and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      (or citrate). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Proximal (type 2) RTA'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HYPOALDOSTERONISM (TYPE 4) RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 4 RTA refers to conditions associated with aldosterone deficiency or resistance. Since aldosterone is the major hormone promoting potassium excretion, hyperkalemia is the primary abnormality in hypoaldosteronism typically accompanied by a mild metabolic acidosis (serum bicarbonate concentration above 17",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and a urine pH of 5.3 or less [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19672/abstract/41,57\">",
"     41,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5491027\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are three major forms of renal tubular acidosis (RTA): distal (type 1), proximal (type 2), and hypoaldosteronism (type 4). Each has a different mechanism by which the acidosis occurs, resulting in different clinical manifestations. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Distal or type 1 RTA is characterized by impaired distal hydrogen ion secretion, leading to severe metabolic acidosis (serum bicarbonate concentration that may fall below 10",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      in the absence of alkali therapy.",
"     </li>",
"     <li>",
"      Different defects impairing distal acid secretion have been identified in distal RTA, which may be associated with markedly different effects on potassium balance. These include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Distal RTA with potassium wasting and hypokalemia may be caused by defects in H-ATPase activity, Cl-HCO3 exchange, or increased luminal membrane permeability to hydrogen ions or carbonic acid (H2CO3).",
"     </li>",
"     <li>",
"      Distal RTA with hyperkalemia, called distal &ldquo;voltage-dependent&rdquo; RTA, is due to impaired sodium reabsorption by principal cells in the cortical collecting tubule. This disorder has many clinical features in common with type 4 RTA; however, aldosterone levels are normal and a more severe distal acidification defect is usually present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incomplete distal RTA is characterized by a persistently high (&gt;5.5) urine pH and hypocitraturia, but a serum bicarbonate concentration in the normal range. Acid excretion is maintained by an increase in ammonium excretion. Some patients with incomplete distal RTA progress to the complete form. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Incomplete distal RTA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proximal or type 2 RTA is characterized by a decrease in proximal bicarbonate reabsorptive capacity caused by impairments that involve the luminal sodium-hydrogen exchanger, the basolateral Na-K-ATPase pump, intracellular and luminal carbonic anhydrase, or the sodium-bicarbonate cotransporter. The degree of acidosis is self-limited. Although untreated patients generally have normal serum potassium, those who are treated with alkali have potassium wasting and hypokalemia. (See",
"      <a class=\"local\" href=\"#H42786907\">",
"       'Proximal (type 2) RTA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H42786914\">",
"       'Effect on potassium excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type 4 RTA is caused by aldosterone deficiency or resistance. Hyperkalemia caused by hypoaldosteronism is typically accompanied by a mild metabolic acidosis (serum bicarbonate concentration above 17",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      and an appropriately low urine pH of 5.3 or less.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, pp. 616-618,623.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/2\">",
"      Sebastian A, McSherry E, Morris RC Jr. Renal potassium wasting in renal tubular acidosis (RTA): its occurrence in types 1 and 2 RTA despite sustained correction of systemic acidosis. J Clin Invest 1971; 50:667.",
"     </a>",
"    </li>",
"    <li>",
"     Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, pp. 357-370.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/4\">",
"      Stanton BA. Renal potassium transport: morphological and functional adaptations. Am J Physiol 1989; 257:R989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/5\">",
"      Young DB. Quantitative analysis of aldosterone's role in potassium regulation. Am J Physiol 1988; 255:F811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/6\">",
"      Poux JM, Peyronnet P, Le Meur Y, et al. Hypokalemic quadriplegia and respiratory arrest revealing primary Sj&ouml;gren's syndrome. Clin Nephrol 1992; 37:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/7\">",
"      Blomqvist SR, Vidarsson H, Fitzgerald S, et al. Distal renal tubular acidosis in mice that lack the forkhead transcription factor Foxi1. J Clin Invest 2004; 113:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/8\">",
"      Kurtzman NA. Disorders of distal acidification. Kidney Int 1990; 38:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/9\">",
"      Batlle DC. Segmental characterization of defects in collecting tubule acidification. Kidney Int 1986; 30:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/10\">",
"      Kim S, Lee JW, Park J, et al. The urine-blood PCO gradient as a diagnostic index of H(+)-ATPase defect distal renal tubular acidosis. Kidney Int 2004; 66:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/11\">",
"      Han JS, Kim GH, Kim J, et al. Secretory-defect distal renal tubular acidosis is associated with transporter defect in H(+)-ATPase and anion exchanger-1. J Am Soc Nephrol 2002; 13:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/12\">",
"      Cohen EP, Bastani B, Cohen MR, et al. Absence of H(+)-ATPase in cortical collecting tubules of a patient with Sjogren's syndrome and distal renal tubular acidosis. J Am Soc Nephrol 1992; 3:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/13\">",
"      Bastani B, Haragsim L, Gluck S, Siamopoulos KC. Lack of H-ATPase in distal nephron causing hypokalaemic distal RTA in a patient with Sj&ouml;gren's syndrome. Nephrol Dial Transplant 1995; 10:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/14\">",
"      Takemoto F, Hoshino J, Sawa N, et al. Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome. Am J Med 2005; 118:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/15\">",
"      Walsh S, Borgese F, Gabillat N, et al. Cation transport activity of anion exchanger 1 mutations found in inherited distal renal tubular acidosis. Am J Physiol Renal Physiol 2008; 295:F343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/16\">",
"      Bruce LJ, Cope DL, Jones GK, et al. Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene. J Clin Invest 1997; 100:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/17\">",
"      Jarolim P, Shayakul C, Prabakaran D, et al. Autosomal dominant distal renal tubular acidosis is associated in three families with heterozygosity for the R589H mutation in the AE1 (band 3) Cl-/HCO3- exchanger. J Biol Chem 1998; 273:6380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/18\">",
"      Karet FE, Gainza FJ, Gy&ouml;ry AZ, et al. Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis. Proc Natl Acad Sci U S A 1998; 95:6337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/19\">",
"      Wrong O, Bruce LJ, Unwin RJ, et al. Band 3 mutations, distal renal tubular acidosis, and Southeast Asian ovalocytosis. Kidney Int 2002; 62:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/20\">",
"      Karet FE. Inherited distal renal tubular acidosis. J Am Soc Nephrol 2002; 13:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/21\">",
"      Yenchitsomanus PT, Vasuvattakul S, Kirdpon S, et al. Autosomal recessive distal renal tubular acidosis caused by G701D mutation of anion exchanger 1 gene. Am J Kidney Dis 2002; 40:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/22\">",
"      Devonald MA, Smith AN, Poon JP, et al. Non-polarized targeting of AE1 causes autosomal dominant distal renal tubular acidosis. Nat Genet 2003; 33:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/23\">",
"      Sritippayawan S, Sumboonnanonda A, Vasuvattakul S, et al. Novel compound heterozygous SLC4A1 mutations in Thai patients with autosomal recessive distal renal tubular acidosis. Am J Kidney Dis 2004; 44:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/24\">",
"      Nicoletta JA, Schwartz GJ. Distal renal tubular acidosis. Curr Opin Pediatr 2004; 16:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/25\">",
"      Toye AM. Defective kidney anion-exchanger 1 (AE1, Band 3) trafficking in dominant distal renal tubular acidosis (dRTA). Biochem Soc Symp 2005; :47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/26\">",
"      Rungroj N, Devonald MA, Cuthbert AW, et al. A novel missense mutation in AE1 causing autosomal dominant distal renal tubular acidosis retains normal transport function but is mistargeted in polarized epithelial cells. J Biol Chem 2004; 279:13833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/27\">",
"      Shayakul C, Alper SL. Defects in processing and trafficking of the AE1 Cl-/HCO3- exchanger associated with inherited distal renal tubular acidosis. Clin Exp Nephrol 2004; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/28\">",
"      Ribeiro ML, Alloisio N, Almeida H, et al. Severe hereditary spherocytosis and distal renal tubular acidosis associated with the total absence of band 3. Blood 2000; 96:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/29\">",
"      Toye AM, Williamson RC, Khanfar M, et al. Band 3 Courcouronnes (Ser667Phe): a trafficking mutant differentially rescued by wild-type band 3 and glycophorin A. Blood 2008; 111:5380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/30\">",
"      Walsh S, Borgese F, Gabillat N, Guizouarn H. Southeast Asian AE1 associated renal tubular acidosis: cation leak is a class effect. Biochem Biophys Res Commun 2009; 382:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/31\">",
"      Karet FE, Finberg KE, Nelson RD, et al. Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet 1999; 21:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/32\">",
"      Vargas-Poussou R, Houillier P, Le Pottier N, et al. Genetic investigation of autosomal recessive distal renal tubular acidosis: evidence for early sensorineural hearing loss associated with mutations in the ATP6V0A4 gene. J Am Soc Nephrol 2006; 17:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/33\">",
"      Wingo CS, Smolka AJ. Function and structure of H-K-ATPase in the kidney. Am J Physiol 1995; 269:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/34\">",
"      Dafnis E, Spohn M, Lonis B, et al. Vanadate causes hypokalemic distal renal tubular acidosis. Am J Physiol 1992; 262:F449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/35\">",
"      Douglas JB, Healy JK. Nephrotoxic effects of amphotericin B, including renal tubular acidosis. Am J Med 1969; 46:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/36\">",
"      Batlle DC, Arruda JA, Kurtzman NA. Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med 1981; 304:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/37\">",
"      Sabatini S, Kurtzman NA. Enzyme activity in obstructive uropathy: basis for salt wastage and the acidification defect. Kidney Int 1990; 37:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/38\">",
"      Batlle D, Itsarayoungyuen K, Arruda JA, Kurtzman NA. Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies. Am J Med 1982; 72:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/39\">",
"      Bastani B, Underhill D, Chu N, et al. Preservation of intercalated cell H(+)-ATPase in two patients with lupus nephritis and hyperkalemic distal renal tubular acidosis. J Am Soc Nephrol 1997; 8:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/40\">",
"      Batlle DC, von Riotte A, Schlueter W. Urinary sodium in the evaluation of hyperchloremic metabolic acidosis. N Engl J Med 1987; 316:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/41\">",
"      Batlle DC, Hizon M, Cohen E, et al. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med 1988; 318:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/42\">",
"      Schlueter W, Keilani T, Hizon M, et al. On the mechanism of impaired distal acidification in hyperkalemic renal tubular acidosis: evaluation with amiloride and bumetanide. J Am Soc Nephrol 1992; 3:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/43\">",
"      Buckalew VM Jr, McCurdy DK, Ludwig GD, et al. Incomplete renal tubular acidosis. Physiologic studies in three patients with a defect in lowering urine pH. Am J Med 1968; 45:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/44\">",
"      Donnelly S, Kamel KS, Vasuvattakul S, et al. Might distal renal tubular acidosis be a proximal tubular cell disorder? Am J Kidney Dis 1992; 19:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/45\">",
"      Hamm LL. Renal handling of citrate. Kidney Int 1990; 38:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/46\">",
"      Morris RC Jr, Sebastian A. Alkali therapy in renal tubular acidosis: who needs it? J Am Soc Nephrol 2002; 13:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/47\">",
"      Pongchaiyakul C, Domrongkitchaiporn S, Stitchantrakul W, et al. Incomplete renal tubular acidosis and bone mineral density: a population survey in an area of endemic renal tubular acidosis. Nephrol Dial Transplant 2004; 19:3029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/48\">",
"      Igarashi T, Inatomi J, Sekine T, et al. Mutations in SLC4A4 cause permanent isolated proximal renal tubular acidosis with ocular abnormalities. Nat Genet 1999; 23:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/49\">",
"      Igarashi T, Sekine T, Inatomi J, Seki G. Unraveling the molecular pathogenesis of isolated proximal renal tubular acidosis. J Am Soc Nephrol 2002; 13:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/50\">",
"      Sly WS, Whyte MP, Sundaram V, et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N Engl J Med 1985; 313:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/51\">",
"      Shah GN, Bonapace G, Hu PY, et al. Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation. Hum Mutat 2004; 24:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/52\">",
"      Sonia HL, Mohamed F, Mohamed B, et al. [Osteopetrosis with carbonic anhydrase II deficiency: report of 24 cases]. Tunis Med 2005; 83:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/53\">",
"      McSherry E. Renal tubular acidosis in childhood. Kidney Int 1981; 20:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/54\">",
"      Manz F, Waldherr R, Fritz HP, et al. Idiopathic de Toni-Debr&eacute;-Fanconi syndrome with absence of proximal tubular brush border. Clin Nephrol 1984; 22:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/55\">",
"      Cogan MG, Rector FC Jr. Proximal reabsorption during metabolic acidosis in the rat. Am J Physiol 1982; 242:F499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/56\">",
"      Sebastian A, McSherry E, Morris RC Jr. On the mechanism of renal potassium wasting in renal tubular acidosis associated with the Fanconi syndrome (type 2 RTA). J Clin Invest 1971; 50:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19672/abstract/57\">",
"      DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980; 17:118.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2327 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19672=[""].join("\n");
var outline_f19_13_19672=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5491027\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETERMINANTS OF URINARY POTASSIUM EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DISTAL (TYPE 1) RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Decreased net activity of the proton pump",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Increased luminal membrane permeability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diminished sodium reabsorption in the adjacent principal cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Incomplete distal RTA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42786907\">",
"      PROXIMAL (TYPE 2) RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42786914\">",
"      Effect on potassium excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HYPOALDOSTERONISM (TYPE 4) RTA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5491027\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2327\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2327|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/43/39613\" title=\"figure 1\">",
"      Distal acid secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/8/8335\" title=\"figure 2\">",
"      Mechanism of HCO3 reabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2327|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/42/23211\" title=\"table 1\">",
"      Characteristics of RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/48/18188\" title=\"table 2\">",
"      Major causes of type 1 RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/4/22604\" title=\"table 3\">",
"      Major causes of type 2 RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/0/41995\" title=\"table 4\">",
"      Major causes of hypoaldosteronism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=related_link\">",
"      Chapter 11A: Renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=related_link\">",
"      Chapter 12B: Renal potassium excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15623?source=related_link\">",
"      Hereditary elliptocytosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=related_link\">",
"      Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10759?source=related_link\">",
"      Overview of renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=related_link\">",
"      Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_13_19673="Benign paroxysmal positional vertigo";
var content_f19_13_19673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Benign paroxysmal positional vertigo",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/13/19673/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19673/contributors\">",
"     Jason JS Barton, MD, PhD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/13/19673/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19673/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19673/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19673/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/13/19673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19673/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/13/19673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 27, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some forms of vertigo and nystagmus are evident only with changes in head position with respect to gravity. Both central (eg, brainstem or cerebellum) and peripheral (eg, canalithiasis) vestibular lesions can cause positional nystagmus and vertigo. The distinction between these two entities is important since central lesions often require some intervention.",
"   </p>",
"   <p>",
"    Central positional nystagmus is usually static, in that the nystagmus persists as long as the head is kept in the provoking position. Positional vertigo due to peripheral vestibular pathology is always transient. Observations of the direction of nystagmus, as well as features of latency and fatigability, can help confirm a peripheral localization and make imaging unnecessary. Patients who have nystagmus with atypical features or nystagmus of undetermined origin should be examined for neurologic signs and investigated.",
"   </p>",
"   <p>",
"    Positional nystagmus and vertigo will be reviewed here. An overview of the approach to the patient with vertigo is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign paroxysmal positional vertigo (BPPV) is the most common form of positional vertigo, accounting for nearly one-half of patients with peripheral vestibular dysfunction. Approximately 18 percent of patients seen in dizziness clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/1\">",
"     1",
"    </a>",
"    ] and 25 percent of patients sent for vestibular testing have BPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/2\">",
"     2",
"    </a>",
"    ]. BPPV also accounts for about 20 percent of pediatric referrals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a population-based survey study, the lifetime prevalence of BPPV was 2.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/4\">",
"     4",
"    </a>",
"    ]. The one-year prevalence of BPPV increased with age and was seven times higher in those older than age 60 years, compared with those aged 18 to 39 years. BPPV was more common in women than men in all age groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;BPPV is most commonly attributed to calcium debris within the posterior semicircular canal, known as canalithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/5\">",
"     5",
"    </a>",
"    ]. This debris likely represents loose otoconia (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    crystals) within the utricular sac [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The semicircular canals normally detect angular head accelerations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34165?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of nystagmus\", section on 'Basic clinical vestibular physiology'",
"    </a>",
"    .) Heavy debris in the canal causes inappropriate movement of the endolymph with linear accelerations, such as gravity, and causes the erroneous sensation of spinning when the head shifts with respect to gravity. BPPV less commonly occurs with disease of the anterior (superior) and horizontal semicircular canals, with slightly different clinical manifestations (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Anterior canal BPPV'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Horizontal canal BPPV'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Classic posterior canal BPPV is idiopathic in 35 percent of cases. Prior head trauma, which can be relatively minor, or whiplash injuries are present in approximately 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/2,7\">",
"     2,7",
"    </a>",
"    ] In the remainder, BPPV is a residual effect of a variety of vestibular pathologies, most commonly Meniere disease (30 percent), but also vestibular neuronitis, ear surgery, herpes zoster oticus, and inner ear ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. BPPV has also been reported as an unusual complication of surgery to elevate the floor of the maxillary sinus, possibly through transmission of vibratory or percussive forces [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/9\">",
"     9",
"    </a>",
"    ]. On rare occasions, decompression sickness may cause a similar positional vertigo, possibly due to nitrogen bubbles in the semicircular canals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of horizontal canal BPPV are idiopathic or due to minor head trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/11\">",
"     11",
"    </a>",
"    ]. This problem is occasionally a complication of the maneuvers used to treat posterior canal BPPV.",
"   </p>",
"   <p>",
"    A higher frequency of BPPV has been reported in patients with giant cell arteritis (GCA) than matched controls, suggesting that some cases of BPPV could be caused by ischemic complications of GCA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/12\">",
"     12",
"    </a>",
"    ]. A population-based survey study found that BPPV was independently associated with age, migraine, hypertension, hyperlipidemia, and stroke, also suggesting a potential vascular mechanism for at least some cases of BPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another theory proposes that bone loss might be the source of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    particles that comprise the canalithiasis. In one study of 209 patients with idiopathic BPPV, bone density was lower and the prevalences of osteopenia and osteoporosis were higher in patients compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11970404\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients complain of recurrent episodes of vertigo lasting one minute or less. Although individual episodes are brief, these typically recur periodically for weeks to months without therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/14\">",
"     14",
"    </a>",
"    ]. In one study, the median duration of BPPV was two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/4\">",
"     4",
"    </a>",
"    ]. Episodes are provoked by specific types of head movements, such as looking up while standing or sitting, lying down or getting up from bed, and rolling over in bed. The spells may wax and wane over time; patients often have sudden spontaneous remissions, only to have the episodes recur at a later date. The vertigo may be associated with nausea and vomiting.",
"   </p>",
"   <p>",
"    Patients with BPPV typically have no other neurologic complaints, in contrast to those with central causes of vertigo. Some patients have evidence of prior inner ear damage. Approximately half of patients complain of imbalance between attacks, even after successful treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observing nystagmus during a provoking maneuver solidifies the diagnosis of BPPV in patients with a typical history. Nystagmus is optimally provoked by the Dix-Hallpike (",
"    <a class=\"graphic graphic_figure graphicRef52232 \" href=\"UTD.htm?34/32/35330\">",
"     figure 1",
"    </a>",
"    ) or Barany maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/15\">",
"     15",
"    </a>",
"    ]. With the patient sitting, the neck is extended and turned to one side. The patient is then placed supine rapidly, so that the head hangs over the edge of the bed. The patient is kept in this position until 30 seconds has passed if no nystagmus occurs. The patient is then returned to upright, observed for another 30 seconds for nystagmus, and the maneuver is repeated with the head turned to the other side.",
"   </p>",
"   <p>",
"    In addition to the prototype of posterior canal BPPV, there are three variants: anterior canal, horizontal canal, and pure torsional.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Posterior canal BPPV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Dix-Hallpike maneuver will usually provoke paroxysmal vertigo and nystagmus if posterior canal dysfunction is present in the ear that is turned downward during the exercise.",
"   </p>",
"   <p>",
"    Diagnostic criteria employing the Dix-Hallpike maneuver have been proposed for posterior canal BPPV (",
"    <a class=\"graphic graphic_figure graphicRef52232 \" href=\"UTD.htm?34/32/35330\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nystagmus and vertigo usually appear with a latency of a few seconds and last less than 30 seconds.",
"     </li>",
"     <li>",
"      It has a typical trajectory, beating upward and torsionally, with the upper poles of the eyes beating toward the ground.",
"     </li>",
"     <li>",
"      After it stops and the patient sits up, the nystagmus will recur but in the opposite direction.",
"     </li>",
"     <li>",
"      The patient should then have the maneuver repeated to the same side; with each repetition, the intensity and duration of nystagmus will diminish.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The latency, transience, and fatigability, coupled with the typical mixed",
"    <span class=\"nowrap\">",
"     upbeat/torsional",
"    </span>",
"    direction, establish this as a peripheral vertigo. Variation in these features may occur with peripheral disease but may also indicate a central lesion (",
"    <a class=\"graphic graphic_table graphicRef73213 \" href=\"UTD.htm?18/15/18683\">",
"     table 1",
"    </a>",
"    ). Overall, the sensitivity of the Dix-Hallpike maneuver in patients with BPPV ranges from 50 to 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sometimes patients have typical symptoms of posterior canal BPPV but no nystagmus during the Dix-Hallpike maneuver. In one series of 20 such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/18\">",
"     18",
"    </a>",
"    ], posturographic recordings showed oscillations of their trunk after sitting up, which the authors speculated may indicate chronic canalithiasis in the short arm of the posterior canal. They recommended repetitive sit-ups from the Dix-Hallpike position as a treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Anterior canal BPPV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior canal BPPV (also known as the superior canal BPPV) has similar provoking factors as classic posterior canal BPPV, but the nystagmus is downbeat and torsional, with the top of the eye torting away from the lower ear, ie, ageotropic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/19\">",
"     19",
"    </a>",
"    ]. The latency, duration, and fatigability are similar [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Horizontal canal BPPV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Horizontal canal BPPV is provoked by turning the head while lying down, sometimes by head turns while upright, but not by getting in or out of bed or extending the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/11\">",
"     11",
"    </a>",
"    ]. The nystagmus is elicited by a lateral head turn in the supine position. Horizontal nystagmus beating toward the floor begins after one to eight seconds of turning the affected ear down; it lasts approximately one minute, and after a few seconds of inactivity is followed by a reversal of the nystagmus, which also lasts up to one minute [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/11,22\">",
"     11,22",
"    </a>",
"    ]. A milder nystagmus is seen with the normal ear down, again beating toward the ground. Approximately 25 percent of patients also have posterior canalithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another method of diagnosis horizontal canal BPPV is the &ldquo;bow and lean&rdquo; test [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/23\">",
"     23",
"    </a>",
"    ]. The seated patient first bends their head forward, aligning the horizontal canal with the gravity vector, and then leans their head backward, flipping the horizontal canal 180&deg;. Right horizontal canalithiasis will cause a right beating nystagmus during the bow and a left beating nystagmus during the lean. This test may be better at lateralizing the problem [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/24\">",
"     24",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Recognizing horizontal canal BPPV is important because it requires a different therapeutic maneuver. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Particle repositioning maneuvers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pure torsional BPPV",
"    </span>",
"    &nbsp;&mdash;&nbsp;About one-half of patients with a history of BPPV have a pure torsional nystagmus by the Dix-Hallpike maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/25\">",
"     25",
"    </a>",
"    ]. This type of BPPV may be due to canalithiasis that involves both the anterior and posterior canals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/26\">",
"     26",
"    </a>",
"    ]. Time to remission with repeated repositioning maneuvers is prolonged for pure torsional BPPV compared with posterior BPPV (mean 25 versus 2.5 days, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INVESTIGATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further testing is not indicated with typical posterior canal BPPV. Electronystagmography (ENG), which tests caloric responses and records other eye movements, is normal or reflects preexisting vestibular pathology. ENG is indicated only if preexisting vestibular disease is suspected by history or examination. Neuroimaging is necessary only if nystagmus does not fit the classic posterior canal BPPV profile (",
"    <a class=\"graphic graphic_table graphicRef73213 \" href=\"UTD.htm?18/15/18683\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/2\">",
"     2",
"    </a>",
"    ], and it is likely to be normal in the absence of clinical findings suspicious for central pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of BPPV is uncertain if no nystagmus is seen on examination. However, empiric treatment with liberatory maneuvers in this setting is often effective if the history is highly suggestive of BPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Particle repositioning maneuvers'",
"    </a>",
"    below.) Neuroimaging can then be reserved for those who do not respond to treatment within a few days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four major disorders in the differential diagnosis of BPPV: postural hypotension, chronic unilateral vestibular hypofunction, migrainous vertigo, and central positional vertigo with downbeat nystagmus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Postural hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postural (orthostatic) hypotension can be confused with BPPV since both cause dizziness that is provoked by a positional change. However, orthostatic presyncope is not induced by rolling over in bed or lying down, while 90 percent of patients with BPPV complain that these maneuvers cause dizziness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chronic unilateral vestibular hypofunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic unilateral vestibular hypofunction is associated with transient dizziness after rapid head turns, but these are fleeting, lasting only one to two seconds. In contrast, vertigo from BPPV does not require rapid head turns, and it typically lasts 30 to 60 seconds. Furthermore, vertigo in posterior canal BPPV is provoked by looking up or down, whereas these maneuvers are not necessarily problematic for patients with chronic unilateral hypofunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Migrainous vertigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is a frequent cause of episodic vertigo, and migrainous vertigo (MV) can present as an isolated positional vertigo mimicking BPPV (pseudo BPPV). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H222097335#H222097335\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Migrainous vertigo'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective review of 362 outpatients with positional vertigo identified 10 patients with migrainous positional vertigo, which differed from BPPV by the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A shorter duration of recurrent episodes than BPPV (eg, recurrence over hours to days rather than weeks to months)",
"     </li>",
"     <li>",
"      More frequent recurrences than BPPV",
"     </li>",
"     <li>",
"      Onset at a young age in some patients",
"     </li>",
"     <li>",
"      Migrainous symptoms, often subtle, during episodes with positional vertigo",
"     </li>",
"     <li>",
"      Positional nystagmus atypical for BPPV",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Central positional vertigo and nystagmus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central positional vertigo may occur with lesions of the vestibulocerebellum. The classic ocular motor sign of central positional vertigo is downbeat nystagmus. In some patients, the downbeat nystagmus is present or increased only when lying down, more so when prone than supine. [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Static positional vertigo'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Static positional vertigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with positional vertigo may have nystagmus that persists as long as the provocative position is maintained, termed static positional vertigo. This can occur with either central [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/32\">",
"     32",
"    </a>",
"    ] or peripheral [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/33\">",
"     33",
"    </a>",
"    ] vestibular lesions.",
"   </p>",
"   <p>",
"    The direction of nystagmus is helpful in distinguishing between central and peripheral causes of vertigo. Pure downbeat nystagmus from cerebellar disease can be accentuated in the reclining position and occasionally occurs only in this position [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. The lack of a torsional component to the nystagmus differentiates this from anterior canal benign paroxysmal positional vertigo (BPPV). Other features that indicate central disease are a lack of latency, lack of fatigability, and the inability to suppress nystagmus with vision (",
"    <a class=\"graphic graphic_table graphicRef73213 \" href=\"UTD.htm?18/15/18683\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76359 \" href=\"UTD.htm?29/33/30235\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The main consideration in the differential diagnosis of positional downbeat nystagmus is the anterior canal form of BPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with static positional nystagmus without prior evidence of more typical BPPV should be investigated for central disease. Lesions of the cerebellar vermis in particular are associated with static positional nystagmus. Possible causes include Chiari malformation, idiopathic cerebellar degeneration, and spinocerebellar ataxia type 6 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/31,38\">",
"     31,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=see_link&amp;anchor=H10#H10\">",
"     \"The spinocerebellar ataxias\", section on 'SCA6'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alcohol can also induce a static positional vertigo with horizontal nystagmus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/39\">",
"     39",
"    </a>",
"    ]. The nystagmus beats toward the floor with the head supine and lateral. This can be shown within 30 minutes of ingestion, peaking at two hours. As the blood alcohol level falls four to five hours later, the nystagmus recurs in the opposite direction and may last up to 12 hours. Nystagmus is attributed to more rapid diffusion of alcohol into the cupula than the endolymph. The resulting difference in specific gravity temporarily imparts an abnormal sensitivity to linear acceleration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Particle repositioning maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several \"liberatory\" or \"particle repositioning\" maneuvers have been devised to treat patients with BPPV (",
"    <a class=\"graphic graphic_figure graphicRef61361 \" href=\"UTD.htm?23/46/24294\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/40\">",
"     40",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Epley maneuver [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/41\">",
"       41",
"      </a>",
"      ] (",
"      <a class=\"graphic graphic_figure graphicRef61361 \" href=\"UTD.htm?23/46/24294\">",
"       figure 2",
"      </a>",
"      ) and modified Epley maneuver (",
"      <a class=\"graphic graphic_figure graphicRef50861 graphicRef62612 \" href=\"UTD.htm?30/17/31002\">",
"       figure 3A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Semont maneuver [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/42\">",
"       42",
"      </a>",
"      ] and modified Semont maneuver (",
"      <a class=\"graphic graphic_figure graphicRef60002 \" href=\"UTD.htm?30/48/31489\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The single treatment maneuvers encourage the debris to migrate toward the common crus of the anterior and posterior canals and exit into the utricular cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/20\">",
"     20",
"    </a>",
"    ]. As noted above, these maneuvers may be effective when the history is highly suggestive of BPPV, even if nystagmus is not seen on examination [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of the Epley maneuver has been demonstrated in studies comparing it with a sham maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. In one report, analysis one month after treatment found that patients who had the particle repositioning maneuver had significantly more negative responses on the Dix-Hallpike maneuver than the placebo group (89 versus 27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/43\">",
"     43",
"    </a>",
"    ]. In a second report, significantly more patients reported resolution of symptoms at 10 days after the particle repositioning compared with sham maneuver (50 versus 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/44\">",
"     44",
"    </a>",
"    ]. In the short term, repositioning maneuvers may be even more efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]; 24 hours after treatment, patients receiving the Epley maneuver were more likely to be free of vertigo and nystagmus compared with patients in the sham group (80 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/45\">",
"     45",
"    </a>",
"    ]. The success of the procedure can be predicted by inspection of nystagmus during the second position of the Epley's procedure; reversed nystagmus direction or no nystagmus observed at this point suggests that the procedure will not be efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systematic reviews have concluded that particle repositioning maneuvers are safe and effective for the treatment of posterior canal BPPV. Treated subjects are 37 times more likely to recover than subjects undergoing sham treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. The Semont and Epley maneuvers appear to be equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/53\">",
"     53",
"    </a>",
"    ], although the Semont is less well studied. The maneuver can be repeated in patients who do not respond to or relapse after the first attempt.",
"   </p>",
"   <p>",
"    After successful re-positioning treatment, up to 37 percent of subjects can still have some mild non-positional vague imbalance and dizziness for two to three weeks; this is more common in older patients and in those whose BPPV had been present for over a week before treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postural restriction, using a cervical collar, and maintaining an up-right head position for two days after treatment has been recommended to prevent return of particles into the semicircular canal. While one study found that patients instructed to restrict head motion were less likely to require retreatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/55\">",
"     55",
"    </a>",
"    ], other studies have not found a benefit for postmaneuver activity restrictions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/51,56\">",
"     51,56",
"    </a>",
"    ]. A meta-analysis of six studies (523 patients) found that restriction of head movement after repositioning did not appear to affect the efficacy of the maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Self-treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the same principles, exercises for home, self-treatment use have been developed: the Brandt-Daroff exercises (",
"    <a class=\"graphic graphic_figure graphicRef63738 \" href=\"UTD.htm?30/7/30833\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/20\">",
"     20",
"    </a>",
"    ], a modified Epley's maneuver (",
"    <a class=\"graphic graphic_figure graphicRef50861 graphicRef62612 \" href=\"UTD.htm?30/17/31002\">",
"     figure 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/58\">",
"     58",
"    </a>",
"    ], and the modified Semont maneuver (",
"    <a class=\"graphic graphic_figure graphicRef60002 \" href=\"UTD.htm?30/48/31489\">",
"     figure 4",
"    </a>",
"    ). Self treatments are likely to be most effective when instruction includes a demonstration of the procedure as well as provision of printed directions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 54 patients found that vertigo resolved in 18 of 28 patients (64 percent) using the modified Epley maneuver compared with 6 of 26 patients (23 percent) using the Brandt-Daroff exercises [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study of 70 patients by the same group found that self-treatment with the modified Epley maneuver was more effective in abolishing vertigo than self-treatment with the modified Semont maneuver (response rate 95 versus 58 percent, respectively), likely because patients had more difficulty performing the latter [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial in 80 patients treated with the Epley procedure alone versus the Epley procedure supplemented by self-treatment with the modified Epley maneuver found that combined therapy resulted in a higher rate of symptom resolution (88 versus 77 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/62\">",
"       62",
"      </a>",
"      ]. This finding was not replicated in another prospective study that found similar treatment responses with these two approaches [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, Brandt-Daroff exercises are less effective than particle repositioning maneuvers; self-treatment with either modified Epley's or Semont maneuver has not been well-studied in comparison to more standard particle repositioning maneuvers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/51\">",
"     51",
"    </a>",
"    ]. Self-treatment with the modified Epley maneuver may serve a complementary role for patients who do not respond immediately to the single treatment maneuvers listed above, and it may become part of the routine management of BPPV for those with frequent recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/60,63\">",
"     60,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The maneuvers are well tolerated by most patients. However, approximately 6 percent have the debris migrate into the anterior or horizontal canals, causing other variants of positional vertigo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/21,62\">",
"     21,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anterior and horizontal canal variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same liberatory maneuvers used for posterior canal BPPV can be used to treat the anterior canal variant. However, few studies have reported treatment for anterior canal BPPV. The scarcity of data is likely a consequence of the rarity of this condition. One study reported success using a \"reverse Epley\" maneuver in two of four patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/64\">",
"     64",
"    </a>",
"    ]. A later study reported benefit with a \"prolonged forced position\" procedure (requiring hospitalization and a head-positioning pulley system) in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/65\">",
"     65",
"    </a>",
"    ]. One study of 14 patients with anterior canal BPPV reported that vertiginous symptoms appeared to resolve as rapidly following repositioning as did posterior canal BPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different maneuvers are used for horizontal canal BPPV than for posterior canal type BPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/11,67\">",
"     11,67",
"    </a>",
"    ]. One better-studied maneuver for the horizontal canal variant involves stepwise rotations of the non-tilted head in the supine position moving 360 degrees from the affected to the unaffected ear [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/51,68,69\">",
"     51,68,69",
"    </a>",
"    ]. This is performed two to four times or until nystagmus disappears. This method has been dubbed the \"barbecue rotation\" maneuver, and is known as the Lempert roll maneuver. The efficacy of this maneuver may depend upon correct determination of the side of the problem, which may be improved by the &ldquo;bow and lean&rdquo; test [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Horizontal canal BPPV'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of BPPV is not well studied, although it is widely accepted that untreated episodes usually resolve spontaneously over days to weeks or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/70\">",
"     70",
"    </a>",
"    ]. In a case series of 108 patients with BPPV who did not receive canalith repositioning maneuvers, positional vertigo symptoms disappeared at a mean of 39 days for patients with posterior BPPV and a mean of 16 days for those with horizontal BPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/71\">",
"     71",
"    </a>",
"    ]. Certain etiologies underlying BPPV (eg, ischemia, vestibular neuronitis, trauma) may be associated with a more prolonged course than with idiopathic BPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/8,72\">",
"     8,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrences of BPPV are fairly common. As an example, one study followed 50 patients with BPPV for a mean of 52 months and found that the recurrence rate by one and three years was 18 and 30 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/73\">",
"     73",
"    </a>",
"    ]. In a series of 103 patients followed after treatment, 35 percent had a recurrence by five years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/74\">",
"     74",
"    </a>",
"    ]. Recurrence was more likely in patients older than 40 or with more than three years of symptoms prior to treatment. Patients with horizontal canal BPPV had a higher recurrence rate than those with posterior canal BPPV. Another retrospective five-year review of 118 patients noted a similar recurrence rate of 33 percent for posterior canal BPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/75\">",
"     75",
"    </a>",
"    ]. BPPV that occurs following trauma may be more refractory to treatment and more recurrent than idiopathic BPPV, although this is not uniformly observed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/72,75,76\">",
"     72,75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Daily performance of particle repositioning maneuvers does not affect either the rate of or the time to recurrence in BPPV; patients should cease performing these maneuvers at home once the symptoms of the current bout have resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drugs are not useful for the brief episodes of vertigo associated with BPPV, except when the frequency of spells is very high [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/51\">",
"     51",
"    </a>",
"    ]. However, vestibular suppressants can be used as premedication with liberatory maneuvers, and they may be helpful for patients who would not otherwise tolerate these maneuvers because of discomfort and nausea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13559?source=see_link\">",
"     \"Treatment of vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BPPV is intractable in a very small number of patients. In such patients, surgical occlusion of the posterior canal with bony plugs is an option; success rates of approximately 90 percent have been reported for this procedure in uncontrolled reports [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/40,51,78\">",
"     40,51,78",
"    </a>",
"    ]. This surgery renders the posterior canal permanently nonfunctional; transient postoperative hearing loss and dizziness are very common. Persistent hearing loss occurs in less than 5 percent; hence, impaired hearing in the other ear is a contraindication to this procedure. An argon laser can also be used to induce ossification of the posterior canal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/79\">",
"     79",
"    </a>",
"    ]. Another surgical option is transection of the posterior ampullary nerve, which has a similar reported success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19673/abstract/80\">",
"     80",
"    </a>",
"    ]. Sensorineural hearing loss occurs in 4 to 40 percent of patients; however, the better complication rates appear to be attributed to one surgeon's experience, and most surgeons favor the occlusive procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/31/41460?source=see_link\">",
"       \"Patient information: Dizziness and vertigo (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positional vertigo is a common problem. Both central (eg, brainstem or cerebellum) and peripheral (eg, canalithiasis) vestibular lesions can cause positional nystagmus and vertigo. The distinction between these two entities is important. Central positional nystagmus is usually static, in that the nystagmus persists as long as the head is kept in the provoking position. Positional vertigo due to peripheral vestibular pathology is always transient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Benign paroxysmal positional vertigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign paroxysmal positional vertigo (BPPV) is the most common form of positional vertigo, accounting for nearly one-half of patients with peripheral vestibular dysfunction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BPPV is characterized by recurrent episodes of vertigo lasting one minute or less. BPPV episodes are provoked by specific types of head movements. Although individual episodes are brief, these typically recur periodically for weeks to months without therapy.",
"     </li>",
"     <li>",
"      BPPV is most commonly attributed to calcium debris within the posterior semicircular canal. Classic posterior canal BPPV is idiopathic in 35 percent of cases. There are three BPPV variants: anterior canal, horizontal canal, and pure torsional.",
"     </li>",
"     <li>",
"      Observing nystagmus during the Dix-Hallpike maneuver solidifies the diagnosis of BPPV in patients with a typical history (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Examination'",
"      </a>",
"      above). The diagnosis of BPPV is uncertain if no nystagmus is seen on examination. However, empiric treatment with liberatory maneuvers in this setting is often effective, if the history is highly suggestive of BPPV.",
"     </li>",
"     <li>",
"      Further testing is not indicated with typical posterior canal BPPV. Patients who have nystagmus with atypical features or nystagmus of undetermined origin should be examined for neurologic signs and investigated.",
"     </li>",
"     <li>",
"      The four major disorders in the differential diagnosis of BPPV are postural hypotension, chronic unilateral vestibular hypofunction, migrainous vertigo, and central positional vertigo with downbeat nystagmus.",
"     </li>",
"     <li>",
"      Liberatory (particle repositioning) maneuvers such as the Brandt-Daroff exercises, Semont maneuver, and Epley maneuver are effective treatments for patients with BPPV. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Particle repositioning maneuvers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrences of BPPV are fairly common. Most respond to repeated treatments with one of the liberatory maneuvers such as the Epley.",
"     </li>",
"     <li>",
"      Drugs are not useful for the brief episodes of vertigo associated with BPPV, except when the frequency of spells is very high. However, vestibular suppressants can be used as premedication with liberatory maneuvers.",
"     </li>",
"     <li>",
"      BPPV is intractable in a very small number of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Static positional vertigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nystagmus that persists as long as the provocative position is maintained occurs with static positional vertigo. This can occur with either central or peripheral vestibular lesions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with static positional nystagmus without prior evidence of more typical BPPV should be investigated for central disease. Lesions of the cerebellar vermis in particular are associated with static positional nystagmus.",
"     </li>",
"     <li>",
"      The main consideration in the differential diagnosis of positional downbeat nystagmus is the anterior canal form of BPPV. Alcohol can also induce a static positional vertigo with horizontal nystagmus.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/1\">",
"      Nedzelski JM, Barber HO, McIlmoyl L. Diagnoses in a dizziness unit. J Otolaryngol 1986; 15:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/2\">",
"      Hughes CA, Proctor L. Benign paroxysmal positional vertigo. Laryngoscope 1997; 107:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/3\">",
"      Wiener-Vacher SR. Vestibular disorders in children. Int J Audiol 2008; 47:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/4\">",
"      von Brevern M, Radtke A, Lezius F, et al. Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neurosurg Psychiatry 2007; 78:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/5\">",
"      Hall SF, Ruby RR, McClure JA. The mechanics of benign paroxysmal vertigo. J Otolaryngol 1979; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/6\">",
"      Oas JG. Benign paroxysmal positional vertigo: a clinician's perspective. Ann N Y Acad Sci 2001; 942:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/7\">",
"      Dispenza F, De Stefano A, Mathur N, et al. Benign paroxysmal positional vertigo following whiplash injury: a myth or a reality? Am J Otolaryngol 2011; 32:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/8\">",
"      Lee NH, Ban JH, Lee KC, Kim SM. Benign paroxysmal positional vertigo secondary to inner ear disease. Otolaryngol Head Neck Surg 2010; 143:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/9\">",
"      Sammartino, G, Mariniello, M, Scaravilli, MS. Benign paroxysmal positional vertigo following closed sinus floor elevation procedure: mallet osteotomes vs. screwable osteotomes. A triple blind randomized controlled trial. Clin Oral Implants Res 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/10\">",
"      Dan-Goor E, Eden JC, Wilson SJ, et al. Benign paroxysmal positional vertigo after decompression sickness: a first case report and review of the literature. Am J Otolaryngol 2010; 31:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/11\">",
"      De la Meilleure G, Dehaene I, Depondt M, et al. Benign paroxysmal positional vertigo of the horizontal canal. J Neurol Neurosurg Psychiatry 1996; 60:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/12\">",
"      Amor-Dorado JC, Llorca J, Costa-Ribas C, et al. Giant cell arteritis: a new association with benign paroxysmal positional vertigo. Laryngoscope 2004; 114:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/13\">",
"      Jeong SH, Choi SH, Kim JY, et al. Osteopenia and osteoporosis in idiopathic benign positional vertigo. Neurology 2009; 72:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/14\">",
"      Brandt T, Daroff RB. Physical therapy for benign paroxysmal positional vertigo. Arch Otolaryngol 1980; 106:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/15\">",
"      DIX MR, HALLPIKE CS. The pathology, symptomatology and diagnosis of certain common disorders of the vestibular system. Ann Otol Rhinol Laryngol 1952; 61:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/16\">",
"      Furman JM, Cass SP. Benign paroxysmal positional vertigo. N Engl J Med 1999; 341:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/17\">",
"      Hoffman RM, Einstadter D, Kroenke K. Evaluating dizziness. Am J Med 1999; 107:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/18\">",
"      B&uuml;ki B, Simon L, Garab S, et al. Sitting-up vertigo and trunk retropulsion in patients with benign positional vertigo but without positional nystagmus. J Neurol Neurosurg Psychiatry 2011; 82:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/19\">",
"      Korres S, Riga M, Balatsouras D, Sandris V. Benign paroxysmal positional vertigo of the anterior semicircular canal: atypical clinical findings and possible underlying mechanisms. Int J Audiol 2008; 47:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/20\">",
"      Brandt T, Steddin S, Daroff RB. Therapy for benign paroxysmal positioning vertigo, revisited. Neurology 1994; 44:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/21\">",
"      Herdman SJ, Tusa RJ. Complications of the canalith repositioning procedure. Arch Otolaryngol Head Neck Surg 1996; 122:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/22\">",
"      Han BI, Oh HJ, Kim JS. Nystagmus while recumbent in horizontal canal benign paroxysmal positional vertigo. Neurology 2006; 66:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/23\">",
"      Choung YH, Shin YR, Kahng H, et al. 'Bow and lean test' to determine the affected ear of horizontal canal benign paroxysmal positional vertigo. Laryngoscope 2006; 116:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/24\">",
"      Lee JB, Han DH, Choi SJ, et al. Efficacy of the \"bow and lean test\" for the management of horizontal canal benign paroxysmal positional vertigo. Laryngoscope 2010; 120:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/25\">",
"      Hayashi Y, Kanzaki J, Etoh N, et al. Three-dimensional analysis of nystagmus in benign paroxysmal positional vertigo. New insights into its pathophysiology. J Neurol 2002; 249:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/26\">",
"      Imai T, Takeda N, Uno A, et al. Three-dimensional eye rotation axis analysis of benign paroxysmal positioning nystagmus. ORL J Otorhinolaryngol Relat Spec 2002; 64:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/27\">",
"      Chang MB, Bath AP, Rutka JA. Are all atypical positional nystagmus patterns reflective of central pathology? J Otolaryngol 2001; 30:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/28\">",
"      Haynes DS, Resser JR, Labadie RF, et al. Treatment of benign positional vertigo using the semont maneuver: efficacy in patients presenting without nystagmus. Laryngoscope 2002; 112:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/29\">",
"      Tirelli G, D'Orlando E, Giacomarra V, Russolo M. Benign positional vertigo without detectable nystagmus. Laryngoscope 2001; 111:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/30\">",
"      von Brevern M, Radtke A, Clarke AH, Lempert T. Migrainous vertigo presenting as episodic positional vertigo. Neurology 2004; 62:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/31\">",
"      Marti S, Palla A, Straumann D. Gravity dependence of ocular drift in patients with cerebellar downbeat nystagmus. Ann Neurol 2002; 52:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/32\">",
"      Hallpike, CS. Vertigo of central origin. Proc Roy Soc Med 1962; 55:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/33\">",
"      Baloh RW, Yue Q, Jacobson KM, Honrubia V. Persistent direction-changing positional nystagmus: another variant of benign positional nystagmus? Neurology 1995; 45:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/34\">",
"      Halmagyi GM, Rudge P, Gresty MA, Sanders MD. Downbeating nystagmus. A review of 62 cases. Arch Neurol 1983; 40:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/35\">",
"      Spooner JW, Baloh RW. Arnold-Chiari malformation: improvement in eye movements after surgical treatment. Brain 1981; 104:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/36\">",
"      Yee RD. Downbeat nystagmus: characteristics and localization of lesions. Trans Am Ophthalmol Soc 1989; 87:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/37\">",
"      Bertholon P, Bronstein AM, Davies RA, et al. Positional down beating nystagmus in 50 patients: cerebellar disorders and possible anterior semicircular canalithiasis. J Neurol Neurosurg Psychiatry 2002; 72:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/38\">",
"      Yabe I, Sasaki H, Takeichi N, et al. Positional vertigo and macroscopic downbeat positioning nystagmus in spinocerebellar ataxia type 6 (SCA6). J Neurol 2003; 250:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/39\">",
"      Aschan G, Bergstedt M. Positional alcoholic nystagmus (PAN) in man following repeated alcohol doses. Acta Otolaryngol Suppl 1975; 330:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/40\">",
"      Parnes LS, Agrawal SK, Atlas J. Diagnosis and management of benign paroxysmal positional vertigo (BPPV). CMAJ 2003; 169:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/41\">",
"      Epley JM. The canalith repositioning procedure: for treatment of benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg 1992; 107:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/42\">",
"      Semont A, Freyss G, Vitte E. Curing the BPPV with a liberatory maneuver. Adv Otorhinolaryngol 1988; 42:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/43\">",
"      Lynn S, Pool A, Rose D, et al. Randomized trial of the canalith repositioning procedure. Otolaryngol Head Neck Surg 1995; 113:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/44\">",
"      Froehling DA, Bowen JM, Mohr DN, et al. The canalith repositioning procedure for the treatment of benign paroxysmal positional vertigo: a randomized controlled trial. Mayo Clin Proc 2000; 75:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/45\">",
"      von Brevern M, Seelig T, Radtke A, et al. Short-term efficacy of Epley's manoeuvre: a double-blind randomised trial. J Neurol Neurosurg Psychiatry 2006; 77:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/46\">",
"      Seo T, Miyamoto A, Saka N, et al. Immediate efficacy of the canalith repositioning procedure for the treatment of benign paroxysmal positional vertigo. Otol Neurotol 2007; 28:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/47\">",
"      Oh HJ, Kim JS, Han BI, Lim JG. Predicting a successful treatment in posterior canal benign paroxysmal positional vertigo. Neurology 2007; 68:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/48\">",
"      Hilton M, Pinder D. The Epley (canalith repositioning) manoeuvre for benign paroxysmal positional vertigo. Cochrane Database Syst Rev 2002; :CD003162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/49\">",
"      Woodworth BA, Gillespie MB, Lambert PR. The canalith repositioning procedure for benign positional vertigo: a meta-analysis. Laryngoscope 2004; 114:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/50\">",
"      White J, Savvides P, Cherian N, Oas J. Canalith repositioning for benign paroxysmal positional vertigo. Otol Neurotol 2005; 26:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/51\">",
"      Fife TD, Iverson DJ, Lempert T, et al. Practice parameter: therapies for benign paroxysmal positional vertigo (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2008; 70:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/52\">",
"      Helminski JO, Zee DS, Janssen I, Hain TC. Effectiveness of particle repositioning maneuvers in the treatment of benign paroxysmal positional vertigo: a systematic review. Phys Ther 2010; 90:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/53\">",
"      Herdman SJ, Tusa RJ, Zee DS, et al. Single treatment approaches to benign paroxysmal positional vertigo. Arch Otolaryngol Head Neck Surg 1993; 119:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/54\">",
"      Teggi R, Giordano L, Bondi S, et al. Residual dizziness after successful repositioning maneuvers for idiopathic benign paroxysmal positional vertigo in the elderly. Eur Arch Otorhinolaryngol 2011; 268:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/55\">",
"      Cakir BO, Ercan I, Cakir ZA, Turgut S. Efficacy of postural restriction in treating benign paroxysmal positional vertigo. Arch Otolaryngol Head Neck Surg 2006; 132:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/56\">",
"      Casqueiro JC, Ayala A, Monedero G. No more postural restrictions in posterior canal benign paroxysmal positional vertigo. Otol Neurotol 2008; 29:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/57\">",
"      Devaiah AK, Andreoli S. Postmaneuver restrictions in benign paroxysmal positional vertigo: an individual patient data meta-analysis. Otolaryngol Head Neck Surg 2010; 142:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/58\">",
"      Harvey SA, Hain TC, Adamiec LC. Modified liberatory maneuver: effective treatment for benign paroxysmal positional vertigo. Laryngoscope 1994; 104:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/59\">",
"      Cohen HS, Sangi-Haghpeykar H. Canalith repositioning variations for benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg 2010; 143:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/60\">",
"      Radtke A, Neuhauser H, von Brevern M, Lempert T. A modified Epley's procedure for self-treatment of benign paroxysmal positional vertigo. Neurology 1999; 53:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/61\">",
"      Radtke A, von Brevern M, Tiel-Wilck K, et al. Self-treatment of benign paroxysmal positional vertigo: Semont maneuver vs Epley procedure. Neurology 2004; 63:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/62\">",
"      Tanimoto H, Doi K, Katata K, Nibu KI. Self-treatment for benign paroxysmal positional vertigo of the posterior semicircular canal. Neurology 2005; 65:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/63\">",
"      Furman JM, Hain TC. \"Do try this at home\": self-treatment of BPPV. Neurology 2004; 63:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/64\">",
"      Honrubia V, Baloh RW, Harris MR, Jacobson KM. Paroxysmal positional vertigo syndrome. Am J Otol 1999; 20:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/65\">",
"      Crevits L. Treatment of anterior canal benign paroxysmal positional vertigo by a prolonged forced position procedure. J Neurol Neurosurg Psychiatry 2004; 75:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/66\">",
"      Imai T, Takeda N, Ito M, Inohara H. Natural course of positional vertigo in patients with apogeotropic variant of horizontal canal benign paroxysmal positional vertigo. Auris Nasus Larynx 2011; 38:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/67\">",
"      Lempert T, Tiel-Wilck K. A positional maneuver for treatment of horizontal-canal benign positional vertigo. Laryngoscope 1996; 106:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/68\">",
"      Fife TD. Recognition and management of horizontal canal benign positional vertigo. Am J Otol 1998; 19:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/69\">",
"      Tusa RJ. Vertigo. Neurol Clin 2001; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/70\">",
"      Zucca G, Valli S, Valli P, et al. Why do benign paroxysmal positional vertigo episodes recover spontaneously? J Vestib Res 1998; 8:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/71\">",
"      Imai T, Ito M, Takeda N, et al. Natural course of the remission of vertigo in patients with benign paroxysmal positional vertigo. Neurology 2005; 64:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/72\">",
"      Ahn SK, Jeon SY, Kim JP, et al. Clinical characteristics and treatment of benign paroxysmal positional vertigo after traumatic brain injury. J Trauma 2011; 70:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/73\">",
"      Sakaida M, Takeuchi K, Ishinaga H, et al. Long-term outcome of benign paroxysmal positional vertigo. Neurology 2003; 60:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/74\">",
"      Rashad UM. Long-term follow up after Epley's manoeuvre in patients with benign paroxysmal positional vertigo. J Laryngol Otol 2009; 123:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/75\">",
"      Kansu L, Avci S, Yilmaz I, Ozluoglu LN. Long-term follow-up of patients with posterior canal benign paroxysmal positional vertigo. Acta Otolaryngol 2010; 130:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/76\">",
"      Gordon CR, Levite R, Joffe V, Gadoth N. Is posttraumatic benign paroxysmal positional vertigo different from the idiopathic form? Arch Neurol 2004; 61:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/77\">",
"      Helminski JO, Janssen I, Hain TC. Daily exercise does not prevent recurrence of benign paroxysmal positional vertigo. Otol Neurotol 2008; 29:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/78\">",
"      Parnes LS. Update on posterior canal occlusion for benign paroxysmal positional vertigo. Otolaryngol Clin North Am 1996; 29:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/79\">",
"      Sugio Y, Nomura Y, Oki S. Argon laser irradiation to the semicircular canal. Laryngoscope 1997; 107:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19673/abstract/80\">",
"      Leveque M, Labrousse M, Seidermann L, Chays A. Surgical therapy in intractable benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg 2007; 136:693.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5098 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19673=[""].join("\n");
var outline_f19_13_19673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11970404\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Posterior canal BPPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Anterior canal BPPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Horizontal canal BPPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pure torsional BPPV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INVESTIGATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Postural hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chronic unilateral vestibular hypofunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Migrainous vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Central positional vertigo and nystagmus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Static positional vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Particle repositioning maneuvers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Self-treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anterior and horizontal canal variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Benign paroxysmal positional vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Static positional vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5098\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5098|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/32/35330\" title=\"figure 1\">",
"      Dix Hallpike maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/46/24294\" title=\"figure 2\">",
"      Epley maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/1/32791\" title=\"figure 3A\">",
"      Modified Epleys Left",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/59/30647\" title=\"figure 3B\">",
"      Modified Epleys Right",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/48/31489\" title=\"figure 4\">",
"      Modified Semont maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/7/30833\" title=\"figure 5\">",
"      Brandt Daroff maneuver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5098|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/15/18683\" title=\"table 1\">",
"      Dix Hallpike findings in central vs peripheral vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/33/30235\" title=\"table 2\">",
"      Clinical features of central versus peripheral vertigo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=related_link\">",
"      Approach to the patient with vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34165?source=related_link\">",
"      Overview of nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/31/41460?source=related_link\">",
"      Patient information: Dizziness and vertigo (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13559?source=related_link\">",
"      Treatment of vertigo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_13_19674="Experimental treatment approaches for malignant gliomas";
var content_f19_13_19674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Experimental treatment approaches for malignant gliomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/13/19674/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19674/contributors\">",
"     Tracy Batchelor, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19674/contributors\">",
"     Jeffrey G Supko, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/13/19674/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19674/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19674/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/13/19674/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/13/19674/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/13/19674/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant gliomas are rapidly progressive brain tumors that are classified as anaplastic astrocytoma (AAs), oligodendroglial tumors, and glioblastoma (GBM), based upon their histopathologic features. The prognosis for these patients is poor, even after aggressive treatment that includes surgery, adjuvant radiation therapy (RT), and adjuvant chemotherapy.",
"   </p>",
"   <p>",
"    The development of new approaches to the treatment of malignant gliomas proceeds through clinical trials in the same way as other malignancies. Issues of particular importance in developing agents to treat these patients include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant gliomas include multiple tumor types, with associated differences in natural history and response to treatment (GBMs versus AAs versus oligodendroglial tumors).",
"     </li>",
"     <li>",
"      Concomitant medications (particularly corticosteroids and antiepileptic drugs) can interact with the cytochrome P450 system, thus potentially altering the metabolism of systemic antitumor agents.",
"     </li>",
"     <li>",
"      Accurate assessment of tumor response can be difficult, even with modern imaging modalities. Time to progression and the percentage of patients free from progression at six months are used as surrogate end points that more accurately reflect the antitumor activity of new agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Experimental approaches to improve the effectiveness of treatment for malignant gliomas will be reviewed here. The standard management of these tumors, including surgery, RT, and adjuvant chemotherapy, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"     \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=see_link\">",
"     \"Adjuvant radiation therapy for malignant gliomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"     \"Adjuvant chemotherapy for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF RESPONSE AND PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials as well as patient management decisions require an assessment of both initial response to treatment as well as subsequent evidence of progressive disease. Traditionally, this approach has used the Macdonald criteria which rely upon measurement of areas of contrast enhancement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/1\">",
"     1",
"    </a>",
"    ]. New criteria have been proposed by the Response Assessment in Neuro-Oncology (RANO) working group to address problems in assessing patients with pseudoprogression or in assessing progressive disease in patients with nonenhancing lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4821?source=see_link\">",
"     \"Assessment of disease status and surveillance after treatment in patients with brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CYTOTOXIC CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;New cytotoxic agents to treat malignant gliomas generally have been evaluated in patients with recurrent or progressive disease.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    , now the preferred agent for adjuvant chemotherapy, was developed in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link\">",
"     \"Adjuvant chemotherapy for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445711000\">",
"    <span class=\"h2\">",
"     Temozolomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    , given concurrently with RT and as an adjuvant after RT, has become the standard of care for patients with a glioblastoma. Alternative dose-dense treatment schedules with temozolomide are being studied and may have utility in patients who have failed the standard temozolomide regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. However, the use of these schedules remains experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As part of a phase III trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    with the nitrosourea-based PCV regimen, the standard five-day schedule of temozolomide was compared with a 21-day schedule, repeated every four weeks, in patients with malignant glioma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/6\">",
"     6",
"    </a>",
"    ]. In that trial, which included 223 patients treated with temozolomide, the standard five-day regimen was associated with a significantly longer progression-free and overall survival compared with the 21-day schedule (5.0 versus 4.2 months, and 8.5 versus 6.6 months, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link&amp;anchor=H5#H5\">",
"     \"Adjuvant chemotherapy for malignant gliomas\", section on 'Temozolomide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445711007\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other agents have demonstrated some activity in phase II studies, which was manifested by partial responses on imaging studies. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/8\">",
"     8",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/9\">",
"     9",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/10,11\">",
"     10,11",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/12\">",
"     12",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/13-15\">",
"     13-15",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/16,17\">",
"     16,17",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/18-21\">",
"     18-21",
"    </a>",
"    ], and the topoisomerase inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/22-26\">",
"     22-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, response rates (including stable disease) for monotherapy using these agents average 40 percent, with a median response duration of 26 to 30 weeks. Response rates are usually higher in patients with AA than GBM (50 to 60 versus 25 to 35 percent, respectively) and the median duration of response is longer (30 to 40 weeks versus 20 to 24 weeks). The use of various combinations of these agents may increase the objective response rate somewhat but has not been shown to increase survival.",
"   </p>",
"   <p>",
"    These efforts to improve cytotoxic chemotherapy for malignant gliomas have not increased survival, and the focus of research has shifted to targeted therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TARGETED SYSTEMIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased understanding of the molecular pathways involved in signal transduction, angiogenesis, and cell growth has led to the development of a number of targeted agents. Such molecularly targeted agents are under active evaluation, alone and in various combinations, for patients with malignant gliomas and other tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link\">",
"     \"Overview of angiogenesis inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific molecular targets and agents that are most promising or have been extensively evaluated are reviewed here, although all remain experimental.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vascular endothelial growth factor pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular endothelial growth factor (VEGF) plays a critical role in the development of the abnormal vasculature observed in malignant gliomas and other tumors. Antiangiogenic strategies targeting this pathway include the use of monoclonal antibodies that bind VEGF, small molecule inhibitors of the tyrosine kinases (TKs) activated by the VEGF receptors, and inhibitors of protein kinase C, which is an important downstream component of the VEGF cascade.",
"   </p>",
"   <p>",
"    These approaches have promising activity in patients with malignant gliomas and are under continuing evaluation. The normalization of tumor vasculature induced by these agents can decrease tumor-associated edema and may facilitate the delivery of other agents to the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    , a monoclonal antibody that binds VEGF and prevents its interaction with VEGF receptors on the cell surface, has activity against recurrent malignant gliomas. The role of bevacizumab in the management of patients with malignant gliomas is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36328?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of recurrent malignant gliomas\", section on 'Bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cediranib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cediranib is an oral inhibitor of all of the VEGF receptor TKs, as well as the TKs associated with platelet derived growth factor (PDGF) receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/27\">",
"     27",
"    </a>",
"    ]. In preclinical studies, cediranib decreased tumor vessel permeability and controlled edema despite ongoing tumor growth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 16 patients with recurrent GBM, cediranib caused a structural and functional normalization of tumor vasculature within 24 hours in all patients, as documented by MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. These vascular changes required continuation of therapy, and interruption of drug resulted in a recurrence of vascular abnormalities. The normalization of tumor vasculature was accompanied by a reduction in tumor-associated vasogenic edema. Corticosteroid therapy was reduced or discontinued in all 11 patients who were steroid-dependent at the initiation of cediranib therapy. In a subsequent phase II study, partial responses were seen in 57 percent of patients, based upon tumor measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these results, a phase III trial was conducted in 325 patients with recurrent GBM [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients were randomly assigned to cediranib alone, cediranib plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    , or lomustine alone. There was no statistically significant improvement in progression-free survival (PFS), the primary endpoint of the trial, with either cediranib treatment arm (PFS 92, 125, and 82 days for cediranib alone, cediranib plus lomustine, and lomustine alone, respectively). There was a statistically significant decrease in steroid use with both cediranib treatment regimens, as well as a reduction in contrast enhancing area on neuroimaging.",
"   </p>",
"   <p>",
"    A second phase III trial is being conducted in previously untreated patients with GBM, in which patients are randomly assigned to treatment with either cediranib or placebo, in addition to standard RT plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    (RTOG 0837, NCT01062425). Accrual is complete, and results are pending.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2376475\">",
"    <span class=\"h3\">",
"     Cabozantinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/22/7526?source=see_link\">",
"     Cabozantinib",
"    </a>",
"    is potent inhibitor of the tyrosine kinases associated with MET, VEGFR2 and RET. The rationale for XL184 development is that this agent inhibits both the VEGF pathway and the HGF pathway, which are thought to be involved in the pathogenesis of GBMs, thus inhibiting both angiogenesis and tumor invasion.",
"   </p>",
"   <p>",
"    XL184 is currently being evaluated in a phase II study of patients with progressive glioblastoma. Preliminary results of this study, based upon 153 patients, were presented at the 2010 American Society of Clinical Oncology (ASCO) meeting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/32\">",
"     32",
"    </a>",
"    ]. The objective response rate in patients who had not received prior antiangiogenic therapy was 30 percent at a daily dose of 125",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and the six-month progression-free survival was 25 percent. Additional follow-up and a larger number of treated patients will be required to determine the potential role of this agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Protein kinase C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein kinase C beta is an important component of the VEGF cascade, which appears to be the predominant angiogenic factor for gliomas. Enzastaurin is a potent and selective inhibitor of protein kinase C beta.",
"   </p>",
"   <p>",
"    Although initial results were promising, a phase III trial in which 266 previously treated patients with recurrent malignant glioma were randomly assigned to either enzastaurin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    was terminated early for futility after a planned interim analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/33\">",
"     33",
"    </a>",
"    ]. At the interim analysis, there were statistically nonsignificant differences in progression-free and overall survival rates with enzastaurin compared to lomustine (hazard ratio [HR] for PFS 1.28, 95% CI 0.97-1.70, and HR for death 1.20, 95% CI 0.88-1.65).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H596448581\">",
"    <span class=\"h3\">",
"     Resistance to VEGF pathway inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of inhibition of the VEGF pathway are typically transient and followed by evidence of recurrent tumor. Even in patients with increased progression-free survival in response to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , there may not be an increase in overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/34\">",
"     34",
"    </a>",
"    ]. The mechanism of acquired resistance is an area of ongoing research. Postulated mechanisms include rebound revascularization mediated by VEGF in patients treated with bevacizumab and an altered tumor growth pattern with a shift to a more infiltrating pattern of tumor growth in patients treated with cediranib [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Epidermal growth factor pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidermal growth factor receptor (EGFR) is dysregulated through overexpression, amplification, or activating mutations in the majority of patients with malignant gliomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14169?source=see_link\">",
"     \"Pathogenesis and biology of malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early studies suggested that small molecule inhibitors of the EGFR tyrosine kinase had activity in patients with malignant glioma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. However, neither erlotinib nor gefitinib demonstrated substantial activity in multicenter phase II studies in patients with malignant glioma, either for recurrent disease or as part of the initial treatment regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/39-42\">",
"     39-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monoclonal antibodies directed against the EGFR are under evaluation. Nimotuzumab has shown activity in the pediatric population for the treatment of high-grade gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/43\">",
"     43",
"    </a>",
"    ] and is currently being evaluated in conjunction with RT in a phase III trial in children with diffuse pontine glioma. Another monoclonal antibody targeting the EGFR, a radioimmunoconjugate using I-125 Mab 425, has been evaluated in adults with GBM or malignant glioma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099563\">",
"    <span class=\"h2\">",
"     Phosphatidylinositol 3-kinase pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphatidylinositol 3-kinase (PI3K) initiates activation of Akt and other downstream effectors, including mammalian target of rapamycin (mTOR), which affect tumor cell growth, proliferation and survival. A variety of alterations in the PI3K pathway have been described in malignant glioma, including mutations in",
"    <em>",
"     PIK3A",
"    </em>",
"    and mutations and homozygous deletions in the phosphatase and tensin homolog (",
"    <em>",
"     PTEN",
"    </em>",
"    ) gene, which counteracts PI3K activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phase II studies have evaluated mTOR antagonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , either alone or in combination with EGFR tyrosine kinase inhibitors, with negative results in unselected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Novel agents with a presumed broader range of activity are currently being evaluated in patients with newly diagnosed and recurrent glioblastoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Platelet derived growth factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet derived growth factor receptor (PDGFR) is overexpressed in malignant gliomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14169?source=see_link\">",
"     \"Pathogenesis and biology of malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhibition of PDGFR has given only limited evidence of activity in treating patients with malignant gliomas.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    , a potent inhibitor of multiple tyrosine kinase receptors including PDGFR, showed evidence of activity in a phase II study when combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/48\">",
"     48",
"    </a>",
"    ]. However, more extensive phase II studies have shown only minimal evidence of single agent activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Integrin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Integrins are involved in endothelial cell proliferation and migration. Cilengitide is a cyclic pentapeptide that acts as a selective integrin antagonist, has direct antitumor activity, and inhibits angiogenesis.",
"   </p>",
"   <p>",
"    Cilengitide has been evaluated in phase I and phase II studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/51-54\">",
"     51-54",
"    </a>",
"    ], which have confirmed that this agent is well tolerated, and suggested that it may improve survival in patients with newly diagnosed GBM when used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    plus RT.",
"   </p>",
"   <p>",
"    Two phase III randomized trials in patients with newly diagnosed GBM have been initiated, one for patients whose tumors have a methylated promotor of the methylguanine-DNA methyltransferase (MGMT) gene and one for those with unmethylated promotors, in which patients are randomly assigned to standard radiation therapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    or the same treatment plus cilengitide (NCT00689221 and NCT00813943) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Histone deactylase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histone deacetylase inhibitors are a novel class of agents that can induce tumor cell growth arrest, differentiation, or apoptosis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/29/27093?source=see_link\">",
"     Vorinostat",
"    </a>",
"    is an orally active agent in this class that is used in the treatment of cutaneous T-cell lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link&amp;anchor=H47#H47\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\", section on 'Emerging novel therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/29/27093?source=see_link\">",
"     Vorinostat",
"    </a>",
"    is under evaluation for patients with recurrent GBM. In a phase II study, 66 patients were with treated vorinostat [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/56\">",
"     56",
"    </a>",
"    ]. Overall, nine of the first 52 patients (17 percent) were progression-free at six months, which met the predetermined requirement for further evaluation. The most common severe side effects were thrombocytopenia and fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BIOLOGIC APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various biologic approaches have been evaluated to treat patients with malignant glioma. Those that have been most extensively evaluated or show promise are discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Interferons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferons are immune modulators that stimulate antiviral and cytotoxic activity by inducing the expression of several cellular genes, a number of which participate in regulation of cell growth and apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both interferon alpha (IFNa) and interferon beta (IFNb) have been evaluated in phase I and II clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/59-64\">",
"     59-64",
"    </a>",
"    ]. Encouraging response rates and survival times were reported when interferon was combined with systemic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/62,65,66\">",
"     62,65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, IFNa was ineffective in a phase III trial, in which 383 patients with newly diagnosed malignant glioma were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    with or without IFNa (12",
"    <span class=\"nowrap\">",
"     mU/m2",
"    </span>",
"    on days 1 to 3, during weeks 1, 3, and 5, every seven weeks) following RT [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/67\">",
"     67",
"    </a>",
"    ]. IFNa did not significantly improve either the time to progression or overall survival, and treatment-related toxicity was increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticancer vaccines stimulate the host immune system to recognize the cancer as foreign. Because brain tumors do not elicit an effective immune response, vaccine therapy requires that the tumor sample be exposed to an agent that enhances the ability of antigen-presenting cells to stimulate an immune response.",
"   </p>",
"   <p>",
"    Several different approaches are under exploration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One approach has focused on dendritic cells [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/68-71\">",
"       68-71",
"      </a>",
"      ]. In two pilot studies, tumor lysates were used to stimulate dendritic cells, which were then used as a vaccine. Systemic cytotoxicity was elicited in the majority of treated patients, and modest antitumor activity was shown in two patients [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/68,69\">",
"       68,69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an alternative approach, an autologous vaccine was prepared from tumor cell cultures that were infected with Newcastle disease virus [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/71-73\">",
"       71-73",
"      </a>",
"      ]. Two pilot studies showed some evidence than an immune response was stimulated, although only one suggested a survival benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A mutated variant in the epidermal growth factor receptor (EGFR) has a tumor specific sequence that is expressed in approximately one-third of GBMs. A peptide sequence from this EGFR variant III (EGFRvIII) has been incorporated into a vaccine (rindopepimut, CDX-110) that is being evaluated in patients with GBM [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/74\">",
"       74",
"      </a>",
"      ]. In a phase II study, patients whose tumor expressed EGFRvIII underwent surgical resection and postoperative RT with concurrent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      , and were then treated with the monthly vaccine. Both progression-free and overall survival appeared to be prolonged compared with contemporaneously treated controls. A phase III trial has been started comparing the EGFR variant III vaccine plus temozolomide with a control arm of keyhole limpet hemocyanin (KLH) plus temozolomide (NCT01480479) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene therapy involves the transfer or modification of a gene in tumor cells to stimulate a local immune response, replace a lost gene, block transcription, increase the sensitivity of a tumor to administered drugs, provide an enzyme that catalyzes the production of a cytotoxic product, or to transfect a tumoricidal virus.",
"   </p>",
"   <p>",
"    A variety of approaches have been used for gene delivery, including the direct introduction of a gene and the use of various viral vectors. The most common experimental approach has been the introduction of the herpes simplex virus thymidine kinase gene into the tumor using a viral vector [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/76\">",
"     76",
"    </a>",
"    ]. If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is subsequently administered, it is phosphorylated by the thymidine kinase gene, leading to the production of toxic triphosphates that block DNA replication [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/77\">",
"     77",
"    </a>",
"    ]. The diffusion of phosphorylated nucleosides away from dying cells to adjacent non-transduced tumor cells causes a \"bystander effect\", resulting in their death. Potential limitations of this strategy include lack of transduction of tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/78-80\">",
"     78-80",
"    </a>",
"    ], transduction of endothelial cells, and immunologic rejection of the murine vector cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     BLOOD-BRAIN BARRIER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important factor affecting the delivery of drug to the brain and brain tumors is the transport of the agent across the blood-brain barrier (BBB) and the blood tumor barrier (BTB). The effectiveness of getting drugs across the BBB and BTB is also influenced by the regional blood flow and drug pharmacokinetic profile.",
"   </p>",
"   <p>",
"    Strategies to increase drug delivery to brain tumors have included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intraarterial drug administration",
"     </li>",
"     <li>",
"      Disruption of the BBB by hyperosmolar solutions or biomolecules",
"     </li>",
"     <li>",
"      High-dose chemotherapy",
"     </li>",
"     <li>",
"      Direct intratumoral injection of free drug, or the use of drug embedded in a controlled-release, biodegradable matrix delivery system",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even if the BBB is overcome, drug access to tumor cells may be hindered by increased intercapillary distances, greater interstitial pressure, lower microvascular pressure, and the uptake of drug by normal brain tissue (the so-called \"sink effect\") [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     BBB characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The capillary endothelium comprising the BBB consists of a sheet of epithelium-like cells connected by tight junctions on a basement membrane that lacks fenestrations. The physiologic role of the BBB is assumed to include maintenance of a constant biochemical environment in the interstitium; the BBB forms a barrier that is relatively impermeable to many water-soluble compounds and protects the brain from foreign molecules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=see_link&amp;anchor=H5#H5\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\", section on 'Blood-brain barrier'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although some drugs may be transported across the BBB using specific endothelial cell transport mechanisms, most cytotoxic drugs can gain access to the central nervous system (CNS) by passive diffusion. Drug properties associated with an increased ability to cross the BBB include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lipid-solubility",
"     </li>",
"     <li>",
"      Neutral at physiologic pH",
"     </li>",
"     <li>",
"      Not highly bound to plasma proteins",
"     </li>",
"     <li>",
"      Molecular weight &lt;200",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    and the nitrosoureas fulfill these criteria, and these agents are widely used for the treatment of malignant gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/84\">",
"     84",
"    </a>",
"    ]. Most other cytotoxic drugs are larger, with a molecular weight greater than 200.",
"   </p>",
"   <p>",
"    The normal BBB also expresses the P-glycoprotein on the luminal surface of capillary endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/83,85-87\">",
"     83,85-87",
"    </a>",
"    ]. This transmembrane protein is responsible for the active efflux of many cytotoxic agents from the brain and brain tumor cells. Preclinical studies suggest that agents that reverse the function of P-glycoprotein (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) may increase passage of agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    across the BBB [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/86,88-90\">",
"     86,88-90",
"    </a>",
"    ], but the clinical relevance of these findings is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Blood-tumor barrier",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to normal brain, the neovasculature within brain tumors is characterized by open tight junctions, gap junctions, fenestrations, and numerous intracellular vesicles [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Junctional clefts in the endothelial cells are also present in adjacent brain capillaries that are not in direct contact with the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/93\">",
"     93",
"    </a>",
"    ]. The increased permeability of the BTB is responsible for contrast enhancement of brain tumors on CT and MRI, since iodinated, water-soluble contrast agents do not penetrate areas of the brain with an intact BBB [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The permeability of the BTB varies widely between patients and within different areas of the same tumor, and this results in large variations in the enhancement patterns of malignant brain tumors on contrast studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. The permeability alterations associated with the BTB are typically found in the central part of large malignant gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/98\">",
"     98",
"    </a>",
"    ]; the proliferating edges of these tumors seem to have a normally functioning BBB and typically do not enhance with contrast on CT and MRI. However, approximately 30 percent of patients with malignant gliomas have nonenhancing lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical implications of these findings are twofold:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infiltration of neoplastic cells may extend well beyond the tumor margin, as defined by contrast-enhanced CT or MRI, thus contributing to incomplete tumor resection [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/99,100\">",
"       99,100",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=see_link\">",
"       \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of a selective, normal BBB near the proliferating edge of a brain tumor may result in variable delivery of water-soluble drugs to this region, contributing to the failure of chemotherapy to control disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intraarterial chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarterial (IA) chemotherapy increases the ratio of regional to systemic blood flow, thereby achieving a higher local drug concentration with smaller drug doses. The goal of this approach is to increase the amount of drug passing through the BBB while minimizing systemic side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/102-105\">",
"     102-105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential disadvantages of the IA chemotherapy include the risk of catheter-related complications (eg, thrombosis, bleeding, infection), treatment-related neurotoxicity (orbital and cranial pain, retinal toxicity, leukoencephalopathy, cortical necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/106-108\">",
"     106-108",
"    </a>",
"    ]), and the inability to use drugs that require systemic metabolic activation.",
"   </p>",
"   <p>",
"    Despite these theoretical advantages, at least two phase III trials failed to show a survival benefit for IA chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. The lack of efficacy and the potential toxicity were illustrated by a Brain Tumor Study Group (BTSG) trial in which 315 patients with newly diagnosed malignant glioma were randomly assigned to IA or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    with or without IV 5-fluorouracil (5-FU) and radiation therapy (RT) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/106\">",
"     106",
"    </a>",
"    ]. IA chemotherapy was associated with significantly shorter survival and severe treatment-related toxicity (including irreversible leukoencephalopathy and ipsilateral blindness in 10 and 15 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     BBB disruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug delivery to brain tumors can potentially be improved by increasing the permeability of the BBB with hyperosmolar solutions (most often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    ) that induce an osmotic opening of the BBB and BTB [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/109,110\">",
"     109,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique of BBB disruption is complex, requiring transfemoral angiography and general anesthesia. Potential complications include stroke and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. Although BBB disruption has theoretical advantages, no clinical benefit has been demonstrated with this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     High-dose chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing the administered dose might drive more drug across the BBB by increasing the peak concentration of unbound drug in the circulation, thus helping to overcome chemotherapy resistance. The major dose-limiting toxicity of alkylating agent-based high-dose chemotherapy (HDT) is myelosuppression, which can be overcome by the use of autologous hematopoietic cell rescue.",
"   </p>",
"   <p>",
"    Despite its theoretical advantages, HDT has not made a significant impact on survival for patients with recurrent malignant gliomas, although anecdotal cases of long-term survival have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. The median survival using HDT with hematopoietic cell rescue as a component of initial therapy is comparable to that with local therapy followed by conventional dose chemotherapy in most studies, and treatment-related morbidity is substantial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/115-117\">",
"     115-117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intratumoral drug administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct delivery of a drug into the tumor or a postoperative tumor resection cavity should maximize local drug concentrations while minimizing systemic effects. Two techniques have been used to directly administer drug to the tumor, slow-release systems and direct infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Slow-release carrier systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled-release methods employing various carrier systems permit constant drug delivery into the tumor while protecting the unreleased drug from metabolism. The most extensively evaluated slow-release system is the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    polymer wafer, which has been approved for use in patients with malignant gliomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=see_link&amp;anchor=H9#H9\">",
"     \"Adjuvant chemotherapy for malignant gliomas\", section on 'Carmustine polymer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Convection enhanced delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The feasibility of direct intratumoral infusion with various chemotherapeutic drugs has been demonstrated in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/118-121\">",
"     118-121",
"    </a>",
"    ]. Contemporary direct drug administration has utilized convection-enhanced delivery (CED) through surgically implanted catheters. CED optimizes the delivery of antitumor agents to the tumor using a positive-pressure infusion to control drug distribution by adjusting the infusion rate and volume [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential utility of CED with small molecule chemotherapy agents was illustrated by a report of 15 patients with recurrent malignant glioma who were treated with CED of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/123\">",
"     123",
"    </a>",
"    ]. There were five complete and six partial responses. Complications included chemical meningitis, infections, and transient neurologic deterioration, which was thought to be due to peritumoral edema.",
"   </p>",
"   <p>",
"    CED may be particularly useful for the delivery of large molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/124\">",
"     124",
"    </a>",
"    ]. As an example, CED has been used to deliver cintredekin besudotox, a conjugate of human interleukin-13 (IL-13) with pseudomonas exotoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/125\">",
"     125",
"    </a>",
"    ]. Malignant gliomas express the IL-13 receptor on the cell surface, and this conjugate is used to deliver locally high concentrations of the pseudomonas exotoxin. A phase III trial to assess the efficacy of this approach&nbsp;in&nbsp;patients with glioblastoma upon&nbsp;first relapse&nbsp;showed no improvement in survival as compared to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    wafers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DIFFERENTIATING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoids are differentiating agents that directly induce cell differentiation in vitro and inhibit cell growth, possibly by stimulating transforming growth factor beta [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/127\">",
"     127",
"    </a>",
"    ]. All-trans retinoic acid (ATRA), cis-retinoic acid, and fenretinide have been evaluated in clinical studies in patients with malignant gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/128-132\">",
"     128-132",
"    </a>",
"    ]. Results with this class of agents are illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ATRA was evaluated in 30 patients with recurrent malignant glioma [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/128\">",
"       128",
"      </a>",
"      ]. Although three patients had partial responses, and the median time to tumor progression and survival were only 3.8 and 5.7 months, respectively.",
"     </li>",
"     <li>",
"      Cis-retinoic acid had modest activity in a phase II study of 80 patients with recurrent malignant glioma [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/129\">",
"       129",
"      </a>",
"      ]. The median progression-free and overall survival durations after treatment initiation were 10 and 25 weeks, respectively, while the six-month progression-free survival was 19 percent. Cis-retinoic acid has been combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      both in patients with recurrent and primary malignant gliomas, without evidence of a synergistic effect [",
"      <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/130,131\">",
"       130,131",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inhibitors of histone deacetylase have also been evaluated as differentiating agents in patients with malignant gliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. In an extensive phase II study, phenylacetate showed little if any activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/133\">",
"     133",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/39/9845?source=see_link\">",
"     Sodium phenylbutyrate",
"    </a>",
"    has been less extensively evaluated, but one prolonged complete remission has been reported with this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RADIOIMMUNOCONJUGATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct administration of radiolabeled monoclonal antibodies into surgically created resection cavities can deliver a highly localized radiation dose to residual tumor, with minimal exposure to normal brain.",
"   </p>",
"   <p>",
"    Tenascin is an extracellular matrix glycoprotein that is expressed in malignant gliomas but not in normal brain. Intracerebral delivery of radioimmunoconjugates directed against tenascin into a surgical resection cavity has been evaluated in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/135-138\">",
"     135-138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No controlled trials have been conducted, but phase II studies suggested an antitumor effect. In one report that included 33 patients with newly diagnosed malignant glioma, the median survival of those with GBM was 79 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/136\">",
"     136",
"    </a>",
"    ]. In another series of 43 patients with locally recurrent malignant brain tumors, the median survival for those with GBM was 64 weeks and 63 percent were alive at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/13/19674/abstract/137\">",
"     137",
"    </a>",
"    ]. A phase III trial is being planned.",
"   </p>",
"   <p>",
"    A radioimmunoconjugate directed against EGFR has also been evaluated as an adjuvant in patients with malignant glioma. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Epidermal growth factor pathway'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant gliomas are associated with a poor long-term prognosis. A variety of approaches have been used to improve results in these patients. The most promising of these rely upon an increasing understanding of the molecular pathways involved in tumor growth, and specific therapies designed against these targets.",
"     </li>",
"     <li>",
"      Multiple agents are in phase I, II, and III evaluation. Patients should be encouraged to participate in clinical studies whenever possible.",
"     </li>",
"     <li>",
"      Efforts to improve cytotoxic chemotherapy for malignant gliomas have not increased survival, and the focus of research has shifted to targeted therapies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cytotoxic chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An increased understanding of the molecular pathways involved in signal transduction, angiogenesis, and cell growth has led to the development of a number of targeted agents, many of which are being actively investigated in patients with malignant glioma. Pathways with particular relevance to malignant glioma include the vascular endothelial growth factor (VEGF) pathway, the epidermal growth factor receptor (EGFR) pathway, and the phosphatidylinositol 3-kinase (PI3K) pathway. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Targeted systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various biologic approaches have been evaluated to treat patients with malignant glioma, including use of interferons, anticancer vaccines, and a variety of gene therapy approaches. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Biologic approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although BBB disruption has theoretical advantages for improved local drug delivery, no clinical benefit has yet been demonstrated with this approach. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Blood-brain barrier'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Differentiating agents such as retinoids and histone deacetylase inhibitors as well as radioimmunoconjugates are also under evaluation. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Differentiating agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Radioimmunoconjugates'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/1\">",
"      Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/2\">",
"      Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/3\">",
"      Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the \"rescue\" approach. Cancer 2008; 113:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/4\">",
"      Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol 2009; 11:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/5\">",
"      Perry JR, B&eacute;langer K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 2010; 28:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/6\">",
"      Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010; 28:4601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/7\">",
"      Wen PY. Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role? J Clin Oncol 2010; 28:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/8\">",
"      Rodriguez LA, Prados M, Silver P, Levin VA. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 1989; 64:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/9\">",
"      Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 1996; 27:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/10\">",
"      Chamberlain MC, Kormanik PA. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 1999; 56:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/11\">",
"      Couldwell WT, Hinton DR, Surnock AA, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996; 2:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/12\">",
"      Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004; 100:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/13\">",
"      Warnick RE, Prados MD, Mack EE, et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 1994; 19:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/14\">",
"      Poisson M, P&eacute;r&eacute;on Y, Chiras J, Delattre JY. Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neurooncol 1991; 10:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/15\">",
"      Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991; 9:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/16\">",
"      Chamberlain MC, Tsao-Wei DD. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 2004; 100:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/17\">",
"      Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer 2006; 106:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/18\">",
"      Chamberlain MC, Kormanik P. Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. J Neurooncol 1999; 43:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/19\">",
"      Postma TJ, Heimans JJ, Luykx SA, et al. A phase II study of paclitaxel in chemona&iuml;ve patients with recurrent high-grade glioma. Ann Oncol 2000; 11:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/20\">",
"      Chamberlain MC, Kormanik P. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 1995; 13:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/21\">",
"      Chang SM, Kuhn JG, Robins HI, et al. A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Cancer 2001; 91:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/22\">",
"      Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003; 97:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/23\">",
"      Batchelor TT, Gilbert MR, Supko JG, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol 2004; 6:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/24\">",
"      Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999; 17:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/25\">",
"      Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 2002; 56:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/26\">",
"      Macdonald D, Cairncross G, Stewart D, et al. Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol 1996; 7:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/27\">",
"      Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/28\">",
"      Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009; 27:2542.",
"     </a>",
"    </li>",
"    <li>",
"     Batchelor T, Sorensen AG, Ancukiewicz M, et al. A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2007; 25:75s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/30\">",
"      Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28:2817.",
"     </a>",
"    </li>",
"    <li>",
"     Batchelor T, Mulholland JP, Neyns B, et al. A phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients (abstract# LBA7). Ann Oncol 2010; 21:viii4.",
"    </li>",
"    <li>",
"     Wen PY, Prados M, Schiff D, et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients with progressive glioblastoma (GB) (abstract #2006). J Clin Oncol 2010; 28:181s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/33\">",
"      Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010; 28:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/34\">",
"      Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011; 29:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/35\">",
"      di Tomaso E, Snuderl M, Kamoun WS, et al. Glioblastoma recurrence after cediranib therapy in patients: lack of \"rebound\" revascularization as mode of escape. Cancer Res 2011; 71:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/36\">",
"      Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005; 97:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/37\">",
"      Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/38\">",
"      Franceschi E, Cavallo G, Lonardi S, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2007; 96:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/39\">",
"      Brown PD, Krishnan S, Sarkaria JN, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 2008; 26:5603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/40\">",
"      van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009; 27:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/41\">",
"      Raizer JJ, Abrey LE, Lassman AB, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 2010; 12:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/42\">",
"      Uhm JH, Ballman KV, Wu W, et al. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys 2011; 80:347.",
"     </a>",
"    </li>",
"    <li>",
"     Bode U, Buchen S, Warmuth-Metz M, et al. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol 2007; 25:76s. (Abstract available online at: www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD, accessed on June 6, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/44\">",
"      Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 2004; 58:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/45\">",
"      Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/46\">",
"      Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23:5294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/47\">",
"      Kreisl TN, Lassman AB, Mischel PS, et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 2009; 92:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/48\">",
"      Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005; 23:9359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/49\">",
"      Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006; 12:4899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/50\">",
"      Raymond E, Brandes AA, Dittrich C, et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008; 26:4659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/51\">",
"      Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007; 25:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/52\">",
"      Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26:5610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/53\">",
"      Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/54\">",
"      Nabors LB, Mikkelsen T, Hegi ME, et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012; 118:5601.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on January 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/56\">",
"      Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009; 27:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/57\">",
"      John WJ, Foon KA. Interferon use in solid tumors. Cancer Treat Res 1998; 94:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/58\">",
"      Kalvakolanu DV. Interferons and cell growth control. Histol Histopathol 2000; 15:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/59\">",
"      Yung WK, Prados M, Levin VA, et al. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 1991; 9:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/60\">",
"      Yung WK, Castellanos AM, Van Tassel P, et al. A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma. J Neurooncol 1990; 9:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/61\">",
"      Allen J, Packer R, Bleyer A, et al. Recombinant interferon beta: a phase I-II trial in children with recurrent brain tumors. J Clin Oncol 1991; 9:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/62\">",
"      Fine HA, Wen PY, Robertson M, et al. A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas. Clin Cancer Res 1997; 3:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/63\">",
"      Fetell MR, Housepian EM, Oster MW, et al. Intratumor administration of beta-interferon in recurrent malignant gliomas. A phase I clinical and laboratory study. Cancer 1990; 65:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/64\">",
"      Colman H, Berkey BA, Maor MH, et al. Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol Phys 2006; 66:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/65\">",
"      Rajkumar SV, Buckner JC, Schomberg PJ, et al. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. Int J Radiat Oncol Biol Phys 1998; 40:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/66\">",
"      Brandes AA, Scelzi E, Zampieri P, et al. Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. Am J Clin Oncol 1997; 20:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/67\">",
"      Buckner JC, Schomberg PJ, McGinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 2001; 92:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/68\">",
"      Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/69\">",
"      Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005; 11:4160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/70\">",
"      Parajuli P, Sloan AE. Dendritic cell-based immunotherapy of malignant gliomas. Cancer Invest 2004; 22:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/71\">",
"      De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008; 14:3098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/72\">",
"      Schneider T, Gerhards R, Kirches E, Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol 2001; 53:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/73\">",
"      Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 2004; 22:4272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/74\">",
"      Blayney DW. Enhancing quality through innovation: American Society of Clinical Oncology presidential address 2010. J Clin Oncol 2010; 28:4283.",
"     </a>",
"    </li>",
"    <li>",
"     U. S. National Institutes of Health, ClinicalTrials.gov file://www.clinicaltrials.gov/ (Accessed on August 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/76\">",
"      Aghi M, Chiocca EA. Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review. Cancer Invest 2003; 21:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/77\">",
"      Ram Z, Culver KW, Walbridge S, et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/78\">",
"      Chiocca EA, Aghi M, Fulci G. Viral therapy for glioblastoma. Cancer J 2003; 9:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/79\">",
"      Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/80\">",
"      Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003; 21:2508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/81\">",
"      Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987; 47:3039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/82\">",
"      Kroll RA, Pagel MA, Muldoon LL, et al. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery 1998; 43:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/83\">",
"      Bart J, Groen HJ, Hendrikse NH, et al. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 2000; 26:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/84\">",
"      Vassal G. [Pharmacologic bases of chemotherapy of brain tumors in children]. Bull Cancer 1990; 77:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/85\">",
"      Henson JW, Cordon-Cardo C, Posner JB. P-glycoprotein expression in brain tumors. J Neurooncol 1992; 14:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/86\">",
"      Fenart L, Bu&eacute;e-Scherrer V, Descamps L, et al. Inhibition of P-glycoprotein: rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an in vitro model of the blood-brain barrier. Pharm Res 1998; 15:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/87\">",
"      Demeule M, Shedid D, Beaulieu E, et al. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int J Cancer 2001; 93:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/88\">",
"      Fellner S, Bauer B, Miller DS, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002; 110:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/89\">",
"      Bowles AP Jr, Pantazis CG, Wansley W. Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study. J Neurosurg 1990; 73:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/90\">",
"      Arboix M, Paz OG, Colombo T, D'Incalci M. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. J Pharmacol Exp Ther 1997; 281:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/91\">",
"      Cucullo L, McAllister MS, Kight K, et al. A new dynamic in vitro model for the multidimensional study of astrocyte-endothelial cell interactions at the blood-brain barrier. Brain Res 2002; 951:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/92\">",
"      Greig NH. Optimizing drug delivery to brain tumors. Cancer Treat Rev 1987; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/93\">",
"      Vick NA, Khandekar JD, Bigner DD. Chemotherapy of brain tumors. Arch Neurol 1977; 34:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/94\">",
"      Steinhoff H, Grumme T, Kazner E, et al. Axial transverse computerized tomography in 73 glioblastomas. Acta Neurochir (Wien) 1978; 42:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/95\">",
"      Blasberg RG, Groothuis DR. Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Semin Oncol 1986; 13:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/96\">",
"      Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 1988; 38:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/97\">",
"      DeAngelis LM. Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan. Ann Neurol 1993; 33:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/98\">",
"      Brooks DJ, Beaney RP, Thomas DG. The role of positron emission tomography in the study of cerebral tumors. Semin Oncol 1986; 13:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/99\">",
"      Kelly PJ, Daumas-Duport C, Scheithauer BW, et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987; 62:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/100\">",
"      Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/101\">",
"      Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980; 30:907.",
"     </a>",
"    </li>",
"    <li>",
"     Greenberg HS, Chandler WF, Sandler HM. Brain tumor chemotherapy and chemotherapy. In: Brain Tumors, Oxford University Press, New York 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/103\">",
"      Bullard DE, Bigner SH, Bigner DD. Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. Cancer Res 1985; 45:5240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/104\">",
"      Levin VA, Kabra PM, Freeman-Dove MA. Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey. J Neurosurg 1978; 48:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/105\">",
"      Yamada K, Ushio Y, Hayakawa T, et al. Distribution of radiolabeled 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitros ourea hydrochloride in rat brain tumor: intraarterial versus intravenous administration. Cancer Res 1987; 47:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/106\">",
"      Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992; 76:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/107\">",
"      Hiesiger EM, Green SB, Shapiro WR, et al. Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A. J Neurooncol 1995; 25:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/108\">",
"      Tamaki M, Ohno K, Niimi Y, et al. Parenchymal damage in the territory of the anterior choroidal artery following supraophthalmic intracarotid administration of CDDP for treatment of malignant gliomas. J Neurooncol 1997; 35:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/109\">",
"      Zlokovic BV, Apuzzo ML. Strategies to circumvent vascular barriers of the central nervous system. Neurosurgery 1998; 43:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/110\">",
"      Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998; 42:1083.",
"     </a>",
"    </li>",
"    <li>",
"     Gumerlock MK, Neuwelt EA. Chemotherapy of brain tumors: innovative approaches. In: Brain Tumors, Morantz RA, Walsh JW (Eds), Marcel Dekker, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/112\">",
"      Neuwelt EA, Howieson J, Frenkel EP, et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 1986; 19:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/113\">",
"      Phillips GL, Wolff SN, Fay JW, et al. Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J Clin Oncol 1986; 4:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/114\">",
"      Abrey LE, Rosenblum MK, Papadopoulos E, et al. High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors. J Neurooncol 1999; 44:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/115\">",
"      Fern&aacute;ndez-Hidalgo OA, Vanaclocha V, Vieitez JM, et al. High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients. Bone Marrow Transplant 1996; 18:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/116\">",
"      Mbidde EK, Selby PJ, Perren TJ, et al. High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer 1988; 58:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/117\">",
"      Durando X, Lemaire JJ, Tortochaux J, et al. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone Marrow Transplant 2003; 31:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/118\">",
"      Patchell RA, Regine WF, Ashton P, et al. A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme. J Neurooncol 2002; 60:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/119\">",
"      Walter KA, Tamargo RJ, Olivi A, et al. Intratumoral chemotherapy. Neurosurgery 1995; 37:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/120\">",
"      Voulgaris S, Partheni M, Karamouzis M, et al. Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol 2002; 25:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/121\">",
"      Boiardi A, Eoli M, Salmaggi A, et al. Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. J Neurooncol 2001; 54:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/122\">",
"      Lopez KA, Waziri AE, Canoll PD, Bruce JN. Convection-enhanced delivery in the treatment of malignant glioma. Neurol Res 2006; 28:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/123\">",
"      Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004; 100:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/124\">",
"      Sampson JH, Akabani G, Friedman AH, et al. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus 2006; 20:E14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/125\">",
"      Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007; 25:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/126\">",
"      Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 2010; 12:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/127\">",
"      Parkinson DR, Smith MA, Cheson BD, et al. Trans-retinoic acid and related differentiation agents. Semin Oncol 1992; 19:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/128\">",
"      Phuphanich S, Scott C, Fischbach AJ, et al. All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J Neurooncol 1997; 34:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/129\">",
"      See SJ, Levin VA, Yung WK, et al. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol 2004; 6:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/130\">",
"      Jaeckle KA, Hess KR, Yung WK, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2003; 21:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/131\">",
"      Butowski N, Prados MD, Lamborn KR, et al. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys 2005; 61:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/132\">",
"      Puduvalli VK, Yung WK, Hess KR, et al. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 2004; 22:4282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/133\">",
"      Chang SM, Kuhn JG, Robins HI, et al. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 1999; 17:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/134\">",
"      Baker MJ, Brem S, Daniels S, et al. Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. J Neurooncol 2002; 59:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/135\">",
"      Cokgor I, Akabani G, Kuan CT, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000; 18:3862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/136\">",
"      Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002; 20:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/137\">",
"      Reardon DA, Akabani G, Coleman RE, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006; 24:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/13/19674/abstract/138\">",
"      Riva P, Franceschi G, Arista A, et al. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 1997; 80:2733.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5178 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-239B17CE44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19674=[""].join("\n");
var outline_f19_13_19674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASSESSMENT OF RESPONSE AND PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CYTOTOXIC CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H445711000\">",
"      Temozolomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H445711007\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TARGETED SYSTEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vascular endothelial growth factor pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cediranib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2376475\">",
"      - Cabozantinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Protein kinase C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H596448581\">",
"      - Resistance to VEGF pathway inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Epidermal growth factor pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6099563\">",
"      Phosphatidylinositol 3-kinase pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Platelet derived growth factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Integrin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Histone deactylase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BIOLOGIC APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Interferons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      BLOOD-BRAIN BARRIER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      BBB characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Blood-tumor barrier",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intraarterial chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      BBB disruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      High-dose chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intratumoral drug administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Slow-release carrier systems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Convection enhanced delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DIFFERENTIATING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RADIOIMMUNOCONJUGATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42391?source=related_link\">",
"      Adjuvant chemotherapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4712?source=related_link\">",
"      Adjuvant radiation therapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4821?source=related_link\">",
"      Assessment of disease status and surveillance after treatment in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/10/17576?source=related_link\">",
"      Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35784?source=related_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36328?source=related_link\">",
"      Management of recurrent malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14169?source=related_link\">",
"      Pathogenesis and biology of malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=related_link\">",
"      Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_13_19675="Distrib RP nodal metastases";
var content_f19_13_19675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distribution of retropharyngeal (RP) lymph nodes metastasis based on stage",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        T stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive RP",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive RP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        2 of 55 (3.6 percent)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        1 of 33 (3 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        14 of 156 (9 percent)",
"       </td>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        7 of 68 (7 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        16 of 76 (21 percent)",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        5 of 51 (9.8 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        22 of 79 (27.8 percent)",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        51 of 214 (19.2 percent)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Yoshimoto S, Kawabata K. Retropharyngeal node dissection during total pharyngolaryngectomy for hypopharyngeal cancer. Auris Nasus Larynx 2005; 32:163.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19675=[""].join("\n");
var outline_f19_13_19675=null;
var title_f19_13_19676="MM urinary monitor";
var content_f19_13_19676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested protocol for monitoring urinary tract disease in a patient with myelomeningocele",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Bladder and renal ultrasound",
"      </td>",
"      <td class=\"subtitle1\">",
"       Voiding cystouretrogram (VCUG)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cystometrogram (CMG) and electromyogram (EMG)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Purpose",
"      </td>",
"      <td>",
"       Detect hydronephrosis, hydroureter, assess bladder wall thickness",
"      </td>",
"      <td>",
"       Detect vesicoureteral reflux, measure bladder capacity and postresidual volume",
"      </td>",
"      <td>",
"       Assess bladder pressure, bladder capacity, urine flow rate, sphincter activity, and bladder emptying",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Birth",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3 to 4 months",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       6 months",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 months",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       12 months",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       18 months",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       24 months",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Every year thereafter",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Every two years thereafter",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    VCUG, CMG, and EMG should be performed more frequently if there is a change in urinary continence, changes in ultrasound findings (eg, hydronephrosis), or recurrent urinary tract infections. Changes in lower urinary tract function may be an early sign of spinal cord tethering. This protocol represents the authors' practice; modified from methods used in Tarcan et al, J Urol 2001; 165:564.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19676=[""].join("\n");
var outline_f19_13_19676=null;
var title_f19_13_19677="Staging of thymic tumors";
var content_f19_13_19677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical staging of thymic epithelial tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Masaoka's clinical stage",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Stage I: Macroscopically completely encapsulated and microscopically no capsular invasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Stage II: Macroscopic invasion into surrounding fatty tissue or mediastinal pleura, or microscopic invasion into capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Stage III: Macroscopic invasion into neighboring organs, ie, pericardium, great vessels, or lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Stage IVa: Pleural or pericardial dissemination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Stage IVb: Lymphogenous or hematogenous metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Koga's proposed pathologic tumor extent of thymic epithelial tumors",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Stage I: Grossly and microscopically completely encapsulated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Stage II: Microscopic transcapsular invasion or macroscopic invasion into thymic or surrounding fatty tissue, or grossly adherent to but not breaking through mediastinal pleura or pericardium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Stage III: Macroscopic invasion of neighboring organ, (eg, pericardium, great vessels, or lung)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Stage IVa: Pleural or pericardial dissemination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Stage IVb: Lymphogenous or hematogenous metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Yamakawa-Masaoka TNM classification and staging",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        T factor:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        T1: Macroscopically completely encapsulated and microscopically no capsular invasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        T2: Macroscopically adhesion or invasion into surrounding fatty tissue or mediastinal pleura, or microscopic invasion into capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        T3: Invasion into neighboring organs, such as pericardium, great vessels, and lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        T4: Pleural or pericardial dissemination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        N factor:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        N0: No lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        N1: Metastasis to anterior mediastinal lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        N2: Metastasis to intrathoracic lymph nodes except anterior mediastinal lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        N3: Metastasis to extrathoracic lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        M factor:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        M0: No hematogenous metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        M1: Hematogenous metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Stage:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage I",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage II",
"       </td>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage III",
"       </td>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stage IVa",
"       </td>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Stage IVb",
"       </td>",
"       <td>",
"        any T",
"       </td>",
"       <td>",
"        N1, 2, 3",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        any T",
"       </td>",
"       <td>",
"        any N",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Masaoka A, Monden Y, Nakahara K, et al. Cancer 1981; 48:2485.",
"       </li>",
"       <li>",
"        Koga K, Matsuno Y, Noguchi M, et al. Pathol Int 1994; 44:359.",
"       </li>",
"       <li>",
"        Yamakawa Y, Masaoka A, Hashimot T, et al. Cancer 1991; 68:1984.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19677=[""].join("\n");
var outline_f19_13_19677=null;
var title_f19_13_19678="Gram stain of normal vaginal flora";
var content_f19_13_19678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal vaginal flora: Gram stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAW8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCI8GnKKdj2pQMGvhT9AE/WpFHFIg+lPANK4mLjpQRgZp2cAcZpT05qREJANN24FSkHPTikBHagZFt9eKZgjOasDrzTWXJ6UBciFODYOafsHak2jPUZ9Kdx6DgcinLksc4wOlQyiRVzEoJ9+adCJFT94ct7UW0EWB2pWQZBNMDdzTy3GaaIYpPtSDrSgjFNY4YYUkUAhT7U4DjmkA70oB69qSBjwAKCDyQM8Uq8/Wn9qb2JIQNwyRg0uynjnIpe3NIZEy803GOnenPKq5JwKjN1HtByMd6pJjSYoBJxQFx1phuEPKniqt5cypHmBNz56cVXK2Uotl/oOTimGRQMk1lxXN1LuEqbCOnBGaGEh5LH6U1DuaKl3NPz0xyaj+0KzYX1rPXJ609ODx2qXFFezSNISZ+lKpDEkVTBYjqalQkL1qeUzcStda3Z2t2Le5Zo29SOK0I5FlUPEwZDyCKqXEFvdDbdW8co7Fhz+dZ8+nXtpdxzaVLmHgNAT90Vvy05JJOz89iNt0b+4AZzwO5OKVgRjOMduaimgWeIxuSN3UqabawJax+WjMy+rYrDoTYlA7U049KeSOe1N7cUmMUHPFHUZFNGaFJxQKxG0ObgSmQjAxtqQKSBxTZVkYARPs96rQ2ciXgmkuHfA+7zj9ab8wLGcMQe/Sl7cdacRx7U1s9h+dK4Irhc/SnYweMUg6ehFLTLHKKcOaQHGKdwKQABmh2VVBY4yQPxp2Oc0fwnihCbGEc81GR81PLUAgmiw7gBg0Fc49qXHGR0qKe7igkWNiTI38I7fWmIk7UFAWBxyKkAGcUuOeemKQrjccHim4wKdj2+tMZhk02NCkUvbrTVO7tTwKAYgzxTgPWmIuCcE80/k/WgQvf2p3OaaMY5p6469aEDIdlwzkrIAOwqWFps7ZlAx3xUg4J9KUHHtVN6E3Adar3c+xcDrUksmxSe9ZzsZpc9hQo9Wa0431Yh3PyTxQyZHQVMFIGKV0B6Dmrua3IkXAFKB9KkA6ZFIRjnFArkTQhyp6YOadIoA4FOGaTdzSHqRlOKQ+lO5yQKUcUDG8jpzUw4HGKjIw3saCewPNKxO5KOAPenq+DUCsQcHpUmQRQ0S0SrJke9Spg1VA4qSJ9owaixDXYsHGMUw49OKQMS2c4XHApwAxnNSyRVxijGBxSjj8KjRpGd90e1B0PPNAhT+lKenFJnnijOeOlMQm3BJz+FNY+mKkPTrUUnHJFIaIByeaeO3FNVcj0p4PYVTLHL75z06UrClXp6Ghw20FRk0EgTimgknFK/y8k+1Nx8uaQyNh89Bzjg07HNKBx04ouMiurg2to0oALA4UH1pmmWhRPtFx808nzZPVe/51LdQJdQiN+ADmrKnCgdh0q72VkJsUfepCc8U4DNRkY6VKJFyAKY3PIpCOeaiDHNNlJEnT8KcpJPSok3ZOelTxgA0A9BwFOK9T/OnKvNOIyKCblZuBzTkBqXyxTlUA9OaSY7h25pCQoyaHOwFm7VTnlPIqkrhGNyK4lLtx3pY0200x8Anr1qRW4wRVnRstBW5yBxml6cZJpi7t3XipGzg7eDRsSAHHNJ+FLk496TtxQIR85qM1I30pv1oKRFgKTjPNZ+vCQ6RceSWEgAI29etaJ4FN7VUZcslLsNq6sNgLC3i3Z3bRnP0qTd0phf5s9qUHnBqWhscGznigttoJAwM49KiduaLCSuTh93FPVuevSqyOq8HilD9TS5ROJaD809X561VRs9aUbsnJqXEnlFbUUF4tumGY+lXt2eKzLW3SAsw5dj1ParBZtwIKhPeiajf3SZR7Fs89OtJg7feoI3IPNTK4PSoasQ00KB3zRnA6UueKYwOeCMVIiqoIk3Z4x0qUMMVGo5qXoBVssVW6U4txxUYGQOakAAFAgUevPtSkdKBSg5I96SExNoFAXORin8cUCgQ1QOlOA696RMEkg5x1p+OaYhOhphIJ4p7cdaaNpPFCAhbO6k25+lWGAz0pCOmKGUmRBealRec05U9qkAwaQNigc0ppQvfNL0ouQN5B6UjHb1pWxGCSfzqhPcEyYzgGnFXLjHmHzyhm2jmmbQeWGCaVIhu3Ek96ewAx6VrtsaKy0RGQCMetRqoVsk8mpiCfpTZANvA5FK5SEByaDxQi96cx5wOp70AIOmaXv0oBwAO9Dfd+lMQ16aexpW5puSBQMaRzmo2H604sabu7frTKQwrzmnhhRx0ppGDQPcVlUkE9RSMBnPvSr34pWHpSAjKBvWlK56GmsWA65xQfc00UPYgHFQ30kq2sjQ43gZApWOelQyTYODTWjuChczYtXLXNqHYKp+V/Y1ZuYLy71ZGlk8qyjGRtPJNVvsdt58kpTczkHB6A+taKy7l74rac4p3proW6bepZu7tLeIMT8pOAaetzgBs8MKy7+P7TCqbsYOanDAoFznAxWDguVWJ9muoLqn2bUEjuHAVzxk9a3PfPB5FcnefYGnia8ZRIhytdHbTxzQqYmyAKVeKspJGNSFiZcdQKNucUAZ9KeOprG5kIFx3qTbmmgVIOntQK4gXselOAA4oJ5FGTnPakgYuAaBx9aOaTvTJAADpwKdnBpOhzTjz1oAhkBJpsSN3qwFGaUdO1FwuN29Pan4/Oj6UpxQxC8ClA4pF6U4ccUkAvTAqN3CZJp74Ck5qj99ySe9NK5UY3CVmlbqQvpQsSnO4U/G3IpAw3BScMe1Uaeg7GOO1Nx2xxUg596bznGOKoSGEhcjFRuoZeKlIByabz6cUFIaBhef0pegpQGJ5xjHT3pQCBQA0Y70EAH1po4JNPApjI9vFQseasN1x3qswwT60JlR1InOR1pD7U1uMnHFNB6qox64pvU0SAsQacpJIzTV5PSnBfpQBMVHXPPWow5BJ/CkkkUDaDlqjEgAJPQdzVcokiUjOajkIXOTSPJjnH0qrcyZHvQlfcuMbsJJSDx0qCR91EZBGG4qJ/vHHSqS6HRGKRIDyMc1MmAuD3qGP1p4DGhjkNc59ab5jIwAUnPcEU5gQCQKg35bFBFrjBZQSTF5vm9q1rUrGFSMlVA6VnnIXjn2qaEsf50Tbno2ZTjdHR9acOlJ1Xg4NKR+VcjOEcPrxTgTTBkilBOPei4D85xk07HFNzioy+AaS1BomXGevNZ9jLcte3CTqfLX7pPerA3N9wjPuKsDJwKtPlvoLyFFO+lIRR9etSSKozS49uKaDTwO/agBAPSlC5Gadxjmo/PjWcQk/OwyAaLArkgGR1pcUIAqgAYGMUpxSAhuW2x+5qui8DFObMkmewNOC4arWhqtEN2tuJJ+XtS7QTkgZ9af7joaADk5poLgoGM00nDEU8nnjimHkcVQkIMD60h5bBpjr8wIzkdKcvKhjwaLFjjhTikYenajr9aUfrSERbcc0uDinlucEUjnptouO4zv0qGRcEkVLkimfWmhrQhkjzio1QAnFXCPlPaq7LzjPFBadyJo/TvUMzHJA6Yqw528DrVK5cL1PAq4o0gm2CgE5IzWXrpMuyyj3/vOWI9Knkvli75qJNQjLZYDI6E1vC8Zc1jdUZPoXGwiLGM7VUDmoZDjoc1KrpKvqKjlXaCV+76VC8xxVnYy9QvhbDy4U865IyIgeauQLI0a+btWTGSF6A01YkEzShAJWGC2OaepIPFXJppKKNEnuyzCgWpME+1MtySfmq2qjGcfWsXuZTdiuY+DnPFRC3HpV3byc09U+XI60N2MuYzzAc1IkZUehq3tGc0x0xS5g5rmygzSNuH8PNIpypHenjgYrmOETpTkyTRjI96enGKAEYH8ary56VcA5yaQoCKExXKkGd1W1FKEAx60rH0p3E9RaMZpBSgdeaBAv606mL1qQc0CFHTrTNiMwZlBZehp3HrSgUDQKeDmonfcSOalOTntUG045oRSGJxn09aeeKztU1B7CEOLdnQMFYjsPWtBXV1VlOQRkEVbi0uboaNDieaRuehoHSlP04pIkcACPwpNo/CpIl3DnPPSlnt2hIV1KEjoavoK+pXIGc00jDZ7U/B7Uu3ggmgq5Gw4pQu0ZNJ34p31pMZG/X2oxk0HGaU9umKBkbrlgfSmsgOMHmpAcUzuTQmMXt1xVZ8hjz0qwz1Ukf5vQ/zpoqKIZWA3E9OlYl/dbQy1r3pIjI69+K5G/kZpDjOMdK6aMbnoYWCk7kNxPyTgmoElBYHP4GmF8E5+lUZZgrEKBivQjC+h6SSS1N61vGi+6eK2IrgSoCK5O3kz161t6cW3AVz1qaWphVprc1BjPrU0cecGkVcGrcKg4rklKxxSlYVIuOBU2zDAevSpFGBwKeM5FYuWpzSlciaPA4FM5Bq0c4561CRlvei5KZGT9abgkcjNTFOO+KTbxQ2VdF9PanbuagiZiB5g2t3FSDrWDOSxKozWZr/iKw0JoEvFlkmm5VUxwM4ySa1FNRTWtvcTxyzwRyyR8oXGcVcHFO81dEsswyrLDHIoIWRQwB6804HimE5JJ60d6zuFh4waRutIKUDimIT1x1pVOSR3owSDgU4Lg0wALk09e9NBxSg0IQ4U4cHmkHNGDSYCSthc1AQT3qy4yKiOQM44FOJSZj6/qNrZ2/kXgkYSjAVBmsnQtWNu8GnG3unDHCyMuAAema6zarEEqpI6bh0pzDcQSBkV0RqxjDl5b/P/AIBd9LDMY6Z5qRVyaT0qSOYxNvXG5fWskyWIrMnTtTJJnmk3SsWIHU0rPvJc9Sc0z145q7gkOAGcjFOkXEYIYZPYVXgcyKdy7ecVI2KaaQ2iIKwK4GR3OaVuho57Gg5xSbuUMxz707GRTQcnFBBGKQxHHIwKRhjmkLc5xTS+Vx0oGkMJx35qqT++NSM4LgNUJYBzirNYor3nfHSudvosEsV4roJm5Oc1WuYQ8RGOCK2py5Dsoz5TjLsElgBis027KwyQQeST1rfvrR45MYOPWqMkHYV6VOpZaM9Jcs0rjLdcEc10GmoWcetZllB833STXSaZa7e1c1epoZV5pIvxoMc1aSPGMHinxRAAAdam2DPHavNlI8iU9RAOho4zin4PAApgADcc+9SjO44AcA9aqxsz3cox+7A4q4PxpGAwcfjihCTsQn2pCOafghulLgD1oZVxqk7s54qTfyKaFzmhVIIzzWdzIsI3FSqTnpUUYwKnCgkZzxzwcUEMQ9aFPzU/bg9qAuCTUoTYozTgeKXj0pQAapE3E69Kr3N1HbTRxynaZDhc1ZCkOSW49Kq6lYxX6RrcBso25SO1VHluubYRZIOc1SudRht3CklmPZatn5VCDOMYzVa2tYrcsUT5mOSTTjy9So26lmJy8YYDGeealzTRn1pCw8zZzn6cVDESk8VHwW708nCZpkZyMmmgQnHpTiaDgCkwKZQhwaAMiggDPGc1Gi7BtB496aGP7UuMikx6GgHBqgEPuaaW9eaJCenSmjA60FWFyBn0prcA80x3HQ01225OePSnYaQrMo69aiMoyc9KhmfdjHXNV5JCDz1qkjaMLloygnrTHfEfvVXdxyeacGBGM07WL5BGc9M575qHkPknFOfIPFIFPciqLWgSYkBPemxEjCsvBpRER0qcICORzQ2F0ivc2ayJnr7VlyaQC+ccVvpuQ4bkU8oG+YYNJVJR2Y415QMi001Ij0rVhhVBhRShSW6VMoAA6ZqJSctzOpVctx0YxT8e3SkXoMjmpBgnpWbMGyLvjHvmmRRuoPmuGz0qbhuhBANBHGaL9AuNxjmkBJQEgA9xTx0NNJwmTwoFMRGWTO3cufTNOAFYehynUNRurk/6qNtiAjFbYJIzg89qurDklysaaauiRV208R5bgU9gFRiTgVm6ks93BsspmX1K8VjFczM4q5YuL22tdonmVWY4Cjkmr0RDoHU5B6VzmneGlWUS3szSSdcA5/WukRAiBVGFHAFXUjTirQd/yFK19B2emaXApMelOArFEsMdhSrSDjqeBTgAR0qiQLYNIzdKMetIwoAOCc44oIzzSgZApccUXAF69KVhznAzTlAx/jS0MVxjfcpq/dqRwCtR9FpopBxgZppOBilJwaQe1BQv8NN2nBpT70A8U0MTHpTW4p7EDBFMxv5PFMEICCehx601uuR3pz4UdKqzTgDiqSuXFN7DpjnOe1UpZc560PcHcec1UIJmLbjg9q0SOmELbkokJI9KjkOWNPZcYPNRc7ulUjRC8ZxmnghVB71Qvr+KwljS4Vwj8mQDhfrVa5v5b+eK00Vt7th3uMZRF9PrWsaM5K/Tv0M51IrTqbaqT9KesWCOMip4YiqKCcnuacAATXPfsS5kcaAk8cU/y6eijaakC4WpZm5FZkxxjg0RxiMnBNTBDknrTgvrRcOYjKE8ihQQ1TgAUx1OalMVwHXml3YIpqjtTwpY0mIE2qMDjPPWhsY5qrczSW2o26tzBJwfbtV1kx9aGrWEyEL0zmnlFZCG6Hihqb04AouIbFBHCpWNcAnJpwUAetHOeKU9u1Id2UvEVzJBp7iFfmPf0qr4d1C2nt+ZQJuhB4raliWRCkgyprKXw/apKXRmU5yF7VpTnTUHCf3iTTjY2UIIGCD6YqQdOKy7O4jgl+zHscZrV96ylGxDVmOHb1pevpTVpIt4UiQ5NSiWOKBgQ2cE54pdoUALwBwKOaOvT0poQzfzin54zxUe3nJPSpPr0pAHWnrUe0dQeakAwKYmKPrUQcsxAx+VSDrSdAcd6AQj4C1Cz88Urlmzu+7UKjrzTijVIUvxigSYph96b34NMtIlMhz14pRIO9QMefam7wo5OKaQ+UtF+KbJINox1quGwDg5NRM+Cec1aiCgTS7mXg81QmBBO7qavbsjjmq9wik56U1uawdimAc0iArMWzkelPCtk8jHalWOrN7icu1O2dKcFAIqdVGwetK5DlYj8qORdk0aupHQipre3ht4RHbxLGg7KMUqx856U/IXgnrSMZSuSAAD3qndyiJHdvuKCxrKvdWv0vmgs9LnnAOPMJ2rS6RcandXjjUtPS3gA4+bcTWnsXFcza+9XIjLXr9zI/CL3F4t3qU7v5c7kQxt0VRxnFdIGGMCkjVI4wiKFUDAAHApqDJJ7moqT9pJytYmKsrDm6+1IO+aUjJ60Hg1BQc5pxPBqN2GcZpwPTFSFhu3uKlU4FIRuFMYc8Umw3HuqOw3KG2nIzTz0pq9s1IRipJZCTt5PAoBBHHNDruJyeO1A4GB0FNgRZweRz61V1C/W127gTn0q4wznjNUr22SddrjIByKcWk9di42b1NXdt5xzWaIbmS/ErSnYO3YCr6cEhjkk0/aeOnvUqXLsZJ2KRsd94J+9aQBH0pqr+dONNybVmKTuxw47UbgOT2pPrSEbuDyKlEscScErgmhSSBkc0wHHQe1DsIkLOQAO9G+gWJccUYqKGZJY90bAg+lSjkUNW0EKOlUNVv3sp7VQm6ORtpPpWhimyRK4HmorAcjIpwaTu1cQpJBG0ZBpCSc04cGkYknAqWNERXCnJqHHJINW9vBBFRFMVS0LUiuR1poGPWrBTOajKYNM0UiI81GVz97NWdlRsh5PcU0UpEBGDweKayjOQTmpdpAPFROdv1q0WtRCdvfio3YConkbvTc5+9Vo1UR46VKDgc1AxXORTg2RnFLUGiRiCQBWdq2rNps8ayQO1u3WUdqvA4Gc1HcBLiJopkV4z1BFaQai7yV0S43LdrOs8avEwaNhkEVm2ml3Mmry3+ozlghIghQ/KB6mrNnGlrCsUC7UHQVdjfj3pc7hdQ6/fYynEexJG0MRTIUJck9qcR36U9BtBrJ+Qr2Q1ic4BpQTxkHNIvXJqTG40r2QhVHHSmSJnJ5FP8AMEbBWzk0kjBR83FIlXuR7Qwx3FSBBgU1T3708Nnt0oGx+PzoVAc5pN2FyTQpzjBqGIXGDxSsOOtLzSE7U+7k5pCGEEjgU0J3qYDJ54+tHAOadxXIGU/T2qvKverjYzmoytFykyUdad6deKQDinCkZDs4GaTrmgkY9qpahfixhaR0yqjPJxTS5nZDSb2L3agZrM0jUjqCGQABOuB2rTB9jROLhK0gYoHJpSqOpRxlSKM/lSDrUiMvTLaazupI8f6O3IrXTtmjHFKg4qpzcndibvqPB57UpPP4U3P50ucmpRInc0c7uvy4qMvJ5+zyz5f97/P8qeeaCrB/k1EWB5Ugj2NSbN6MrcBhjNc1ok72N/caZdlixctESeorWnDnTtuh+Z0J5zRtGaTkcUgJ3+1SUOYelMIHapD2puMtxQgIGFVJoyx5qveam7atFZWcfmkH96f7oq/IuTxWzi4JX6msHYz3i7VGQVIweKtNx1qOQZOVpJnSmV8fMQaC+1eKDncfWmE/MBVovckPODSx8HnrUT5OKfEd2aLCa0JlOKljk/KolXHSnIvr0qTNq5bjO7A9alIwp5qvC2GHHHrUzct14qXuYtage2KXkU1ST2xjpTsjmkyQyuM8EjpntVe6nSOPMmSM9BTLy5WFSzZx7VFBJHcY2FXHXBHI/CrUXuaRh1ZchJcAjpU6pilhXgGpeucVk2ZSlqMxwe/tSqo444FOx+FKBj8Khsm4nDZxz7UycERNg4OOtPwAfSkdQ6lWHBpJ6gV7Ilozgg+2c1MfwqvbWhgnZkY4Y1cKjmqlboEnroQg5BxSgZ6mhgc0vtUAwZgi7m6Core5SfdszkdjT3CsjI2eRWbYWzw3ZbccDjn0rSCi07iS0uaw6Vma3FFKFE6+Yn93pmtNRVLU7Z52TaflHWim0pDg7Mh8PW7RWPMAhUnKjGM1rqOKitkKxIrdQMVOBjpRN80myGxpGaXvSou0AZJ9ycmjv7etQTcM+lIDzTj6UcUAJk5xThyetNx19aUA9qYCnrxSqMUnQnml7DFJgKBxis3WNJXUTBJHJ5NxEwIkHXHpWoPSlA6ZqoycHzR3C/QhdMKOelMzzVkjio2QFqVxpkLUwsR3qcx+9MMZ7000VdFRIIYZJJkjAkf7zDqaXaWXOMCrPl8HtTSuB1q7lqRnzJ6dqrKOp9a1JFHI4yawrG4zd3FtMw3qeK0gnJNrobwldEzkDJqBiACx6CrMiEtjtUcke5SCMjGMVSNotGeuqWsh2rMmQcc1MtxGQMMpJ9DWXN4dsnkY7XUk54NVW8MAH9xdSIPc11WoPq18jTl9Dqo2z0qcEbaydFs5LO3McsplYnIJ9K2I15welc07JtLUwmrDoxx7Uu4k06TCLUQkwT71mZrXUsRsveiZlAOKol234HQmnljnjtSsHJ1GsN+7IBB6gjNRppql1e1bypQc4zx/9aptwzx1q/aDvjmqcmkOUnFaC2UzE+TOu2YH6A1aZSMVHcQpMu1jtI6MKlQbUVWYsVGM1izlb6jCvelGQaftHTtSkDgCoYXG49qTbUmPzpCOfWkK5EBmlI9KeBz/AI00jHU0BcibjpUZODk1Ow64pmzPSpZSYwjPSmhTzxg09RTx1qxXsKo4p2KaDjAp+aCRVFL0qNAcDd174qQcigTF4NJikU4JOaXOTxTEHamO5jjLBdxHanHgelAz9KYEVuZWUvMAuei+lWAeTx0pgGAByfc04dKLA2AHJ96cOuaMUqAgAMcn1xik0FwFPU0gFKRzQhNimm5BbHenHrTEBXOcZz1osFx5FIV6UZznGcUv19KEA0qMdKY8fPFSgjpSjBpgmVTCMf1rLGll9akuSipGFwvv/nrW4uHU7lI57UjJ0x0pqTWxcajRg309vb3qW0jhZHHGe9NaM7iCOateI9GGqWaGLCXkZzG/9KltLaUW0Qu9vnhcMRW948ia36msatjLZBn3qNl5GP5VrTWy9uD2qjLEUPPShNHRGpcgHy4p6uQ3U1E+dwpqvnJU+1Oxe5YdyQajRieDSA8c04HBpWFaxJxyRzTScUqgdutJg+lIQqn5+tX4CVTOapRplqsSN8mOtTIieuhaEoJwDmnrJ2rMj3BqlD47/Ws2iHTRpq+elPU5NVLeQEYGc1bj5PtUMwkrD+nOKCOKcMflSewqSLjMdc/pTUUqMM2aeQd2QaTHr1phcay5HBqM4XqelSt0qndOVxt60i4q+h//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of vaginal swab under high power magnification (1000x) showing mixed bacterial Gram stain morphology consistent with normal vaginal flora",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19678=[""].join("\n");
var outline_f19_13_19678=null;
var title_f19_13_19679="Pancreatic stent migration";
var content_f19_13_19679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal migration of a pancreatic stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pancreatogram demonstrates a pancreatic stent that has migrated into the pancreatic body. A mini-snare has been advanced into the pancreatic duct and is opened beyond the stent to capture its proximal end.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Catalano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_13_19679=[""].join("\n");
var outline_f19_13_19679=null;
